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Two libraries of substituted benzimidazoles were designed using a ‘scaffold-hopping’ approach based on 
reported MDM2-p53 inhibitors. Substituents were chosen following library enumeration and docking into an 
MDM2 X-ray structure. Benzimidazole libraries were prepared using an efficient solution-phase approach, 
and screened for inhibition of the MDM2-p53 and MDMX-p53 protein-protein interactions. Key examples 
showed inhibitory activity against both targets. 
  
INTRODUCTION 
The design of small molecule inhibitors of protein-protein interactions has received considerable 
interest in recent years.(1-4) In particular, the interaction of p53 with the regulatory proteins MDM2 and 
MDMX have provided a focus for efforts because of their importance in a number of cancers, and the 
prospect that inhibition of these interactions may provide new therapies. Overexpression of the regulatory 
proteins MDM2 and MDMX has been demonstrated to silence the tumor suppressor function of p53. MDM2 
amplification occurs in around 11% of all tumors, and is most common in hepatocellular carcinoma (44%), 
osteosarcomas (20%), and soft tissue sarcomas (31%). Similarly, MDMX (MDM4) occurs in approximately 10-
25% of tumors, e.g. brain (11%), breast (5-40%), and sarcomas (17%).(5-8) 
Expression of MDM2 is p53-dependent, and forms a regulatory feedback loop with p53 by binding to 
the p53 transactivation domain. Acting as an E3-ligase, MDM2 promotes proteasomal degradation of p53.(9-
12) MDMX expression is not p53-dependent and MDMX levels remain constant. The protein inhibits p53 
transcriptional activity, but does not act as an E3 ligase independently of MDM2.(13) Thus, MDM2 and 
MDMX both regulate p53, but their functions are different and non-redundant.(14) 
The X-ray crystal structure of MDM2 bound to a p53-derived peptide reveals the -helical peptide 
bound into a deep groove on the surface of the protein, and key interactions are formed with three 
hydrophobic residues of p53 (Figure 1).(15) Inhibitors of MDM2 with diverse chemotypes have been 
reported.(16, 17) X-ray crystal structures of a range of potent MDM2-p53 inhibitors have been published, 
such as Nutlin-3 (1), spirooxindoles, e.g. MI-63 (2) and pyrrolidones (3).(18-21) Inhibitors show cellular 
activity and in vivo antitumor activity.(18, 22) Recently, potent MDM2-p53 inhibitors have entered clinical 
trials, including RG7112,(23, 24) RG7388(25) and MI-773(26) (Chart 1). 
<figure 1, chart 1> 
The p53 transactivation loop binds in a cleft on the surface of MDMX similar to that identified for 
MDM2 but with a closed conformation for Tyr99.(27, 28). Steric hindrance of Met53 in the Leu23 pocket for 
MDMX may be responsible for the lack of potency against MDMX for MDM2-p53 inhibitors such as the 
Nutlins and spirooxindoles.(29) A high degree of flexibility has been measured in computational studies of 
MDMX, and significant conformational differences, owing to the induced fit of ligands are observed in crystal 
 3 
 
structures.(30-32) Reports of small-molecule MDMX-p53 inhibitors have not been as numerous as for 
MDM2.(21) The selective MDMX inhibitor 5-oxo-pyrazolylidene SJ-172550 (4) was identified in an MDMX 
high-throughput assay.(33) The 3-imidazolylindole 5 is a mixed MDM2- and MDMX-p53 inhibitor with 
modest potency against MDMX.(29) Recently, indolylhydantoins, e.g. (6) have been reported as MDM2-p53 
and MDMX-p53 inhibitors.(34)  
<structures 4,5,6> 
In this paper, we describe the application of a scaffold-hopping approach to design new inhibitor 
chemotypes for MDM2 and MDMX(35, 36) based on heterocycle replacement, and derived from two 
MDM2-p53 inhibitors with significantly different core structures. In particular, starting from cis-imidazoline 
(1),(18) and a class of oxindoles (7),(37, 38) benzimidazole derivatives were designed and evaluated through 
docking studies. The benzimidazole heterocycle was chosen as a ‘privileged structure’ in medicinal chemistry 
that is readily synthetically accessible.(39) The synthesis of small libraries yielded mixed MDM2-p53 and 
MDMX-p53 inhibitors with promising potency. 
<structure 7> 
MATERIALS AND METHODS 
MDM2-p53 ELISA assay. Compounds were assayed for MDM2-p53 inhibitory activity using ELISA assays in a 
96-well format using the published method.(40)  
MDMX-p53 ELISA assay. MDMX-p53 inhibitory activity was determined using an analogous method 
incorporating a pCMV-XL5-MDMX cDNA construct (OriGene Technologies) for the in vitro coupled T7 
transcription and rabbit reticulocyte lysate translation of MDMX, and a rabbit anti-MDMX antigen affinity-
purified polyclonal antibody (Bethyl Laboratories Inc, via UK supplier Cambridge Bioscience, UK, Cat No. 
A300-287 A).(41)  
Docking experiments. Docking calculations were performed with the GOLD software.(42) Ligands were 
docked within the p53 binding site of MDM2, using the crystal structure of human MDM2 in complex with 
the small molecule inhibitor Nutlin-2 (PDB code: 1RV1).(18) A single protein chain was selected from the unit 
cell. The binding site was defined by hydrophobic fitting points calculated on the target for a 8Å radius 
around the co-crystallized ligand. GoldScore was used as a fitness function, while default genetic algorithm 
parameter settings were applied. 30 poses were generated for each ligand, early termination being allowed 
when the top 10 solutions were within 1.5Å R.M.S.D. 
Chemical Synthesis. 
General Procedure A – Synthesis of compounds (14). 
 A mixture of the appropriate aldehyde (1.2 eq.), sodium dithionite (86% purity; 1.98 g, 9.78 mmol, 3 eq.) 
and 13 (1.16 g, 3.26 mmol, 1.0 eq.) in methanol (12 mL) and water (3 mL) was heated in a microwave reactor 
for 10 minutes at 100 oC. The sample was diluted with ethyl acetate (20 mL) and washed with water (20 mL) 
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and brine (20 mL). The organic layer was dried (MgSO4), and evaporated. Chromatography (silica; ethyl 
acetate, petrol) gave compound 14. 
General Procedure B. Compound 14 was dissolved in DCM (2 mL) and TFA (3 mL) and the mixture stirred at 
rt for 1 hour, then evaporated. The residue was diluted with DCM (20 mL) and neutralised with sodium 
carbonate (sat.; 20 mL). The organic layer was dried (MgSO4) to give 15 which was used without further 
purification.  
General procedure C. Either an aliquot of a solution of 15 in dry DCM (1 mL, 0.049 M), or weighed 15 in dry 
DCM (1 mL) was treated with the named isocyanate (1.5 eq.). The mixture was quenched with NH2-silica and 
filtered through a plug of NH2-silica. Evaporation gave 8 without further purification.  
 (S)-Ethyl 3-(3-(5-chloro-2-(3-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)piperidine-1-
carboxamido)benzoate 8{3,7}. 
General procedure C: 15{3} (1 mL, 49.3 µmol) and ethyl 3-isothiocyanatobenzoate (12 µl, 76 µmol). 8{3,7} 
(26 mg, 96%) as a white solid; HPLC purity (as area %) > 98; 1H NMR (300MHz, CDCl3) 1.38 (1H, t, J 7.2, 
CH2CH3), 1.54 (1H, qt, J 3.6 and 13.1), 1.72 (1H, app.dd), 1.87 (1H, app.d), 2.20 (1H, qd, J 4.0 and 12.7), 2.80 
(1H, td, J 2.2 and 13.1), 3.38(1H, app.t), 3.63 (3H, s, OCH3), 3.77 (1H, app. dd), 4.21 (1H, app.d), 4.30 (2H, s, 
CH2), 4.36 (2H, q, J 7.2), 6.54 (1H, br.d), 6.65-6.69 (1H, m, Ar), 6.77 (2H, d, J 8.3, Ar), 7.17 (1H, app.t, Ar), 7.20 
(1H, m, Ar), 7.32-7.39 (2H, m, Ar), 7.67-7.81 (4H, m, Ar); 13C NMR (100MHz, CDCl3) 14.3, 24.8, 28.6, 35.0, 
44.1, 47.2, 53.5, 55.2, 61.1, 112.2, 112.5, 114.3, 119.8, 120.5, 121.0, 122.7, 124.4, 124.7, 127.7, 128.9, 129.9, 
131.0, 132.1, 137.5, 138.9, 144.0, 154.2, 154.7, 160.0, 166.3. 
 (S)-Ethyl 3-(3-(5-chloro-2-(4-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)piperidine-1-
carboxamido)benzoate 8{4,7}. 
General procedure C: 15{4} (1 mL, 49 µmol) and 3-isocyanatobenzoate (12 µl, 76 µmol). 8{4,7} (23 mg, 85%), 
white solid; HPLC purity (as area %) > 98; 1H NMR (400MHz, CDCl3) 1.33 (3H, t, J 4.1, CH2CH3), 1.48 (1H, qt, J 
4.1 and 13.3), 1.62 (1H, app.d), 1.82 (1H, app.d), 2.17 (1H, qd, J 4.1 and 12.8), 2.78 (1H, td, J 2.3 and 13.3), 
3.36 (1H, app.t), 3.55 (3H, s, OCH3), 3.82 (1H, dd, J 4.1 and 12.8), 4.15 (1H, d, J 16.0), 4.17 (1H, app.d), 4.23 
(1H, d, J 16.0), 4.25-4.33 (1H, m), 4.30 (2H, q, J 7.3, CH2CH3), 6.70-6.73 (3H, app.d), 7.04 (2H, d, J 8.7, Ar), 7.15 
(1H, dd, J 1.8 and 8.7), 7.28-7.33 (2H, m, Ar), 7.59-7.62 (1H, m, Ar), 7.63-7.70 (2H, m, Ar), 7.81 (1H, app.d, 
Ar); 13C NMR (100MHz, CDCl3) 14.3, 24.9, 28.6, 34.1, 44.2, 47.2, 53.4, 55.0, 61.0, 112.2, 114.2, 119.7, 121.1, 
124.4, 124.8, 127.6, 127.7, 128.9, 129.4, 131.0, 132.2, 139.0, 144.0, 154.7, 154.9, 158.7, 166.3; MS (ESI+) m/z 
= 547.3 [M+H]+. 
 (S)-N-Benzyl-3-(2-benzyl-5-chloro-1H-benzo[d]imidazol-1-yl)piperidine-1-carbothioamide 16.  
General procedure C: 15{1} (16 mg, 49.2 µmol) and benzyl isothiocyanate (7.2 µl, 54.1 µmol). 16 (15 mg, 
64%) as a white solid; HPLC purity (as area %) > 93; 1H NMR (500 MHz, CDCl3) 1.43 (1H, qt, J 4.1 and 13.3), 
1.55 (1H, app.d), 1.77-1.80 (1H, m), 2.25 (1H, qd, J 12.8 and 4.4), 3.03 (1H, td, J 13.4 and 2.4), 3.50 (1H, 
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app.t), 4.35-4.46 (4H, m), 4.67-4.71 (1H,m), 4.74 (1H, dd, J 14.6 and 4.6), 4.97 (1H, dd, J 14.6 and 5.4), 5.65 
(1H, app.t, NH), 7.15-7.22 (6H, m, Ar), 7.30-7.36 (6H, m, Ar), 7.73 (1H, d, J 2.0, Ar); 13C NMR (125 MHz, CDCl3) 
24.5, 28.4, 35.0, 48.0, 50.4, 51.3, 52.7, 112.0, 119.9, 122.7, 127.2, 127.7, 127.8, 127.9, 128.4, 128.8, 128.9, 
132.1, 136.2, 137.8, 144.1, 154.5, 183.2. LC-MS (ESI+) m/z = 475.3 [M+H]+. 
(S)- 2-Benzyl-1-(1-(benzylsulfonyl)piperidin-3-yl)-5-chloro-1H-benzo[d]imidazole 17.  
Phenylmethanesulfonyl chloride (12 mg, 60.9 µmol, 1.1 eq) was added to a solution of 15 (18 mg, 55.4 µmol, 
1eq) and triethylamine (11.6 µl, 83.1 µmol, 1.5 eq) in DCM (1mL). The mixture was stirred at RT for 1h, then 
quenched with water (3mL). The organic layer was separated, dried (MgSO4), and evaporated. 
Chromatography (5% DCM, methanol) gave 17 (25 mg, 94%) as a white solid; HPLC purity (as area %) > 96; 1H 
NMR (500 MHz, CDCl3) 1.34-1.41 (2H, m), 1.64-1.68 (1H, m), 1.94 (1H, qd, J 12.6 and 4.2), 2.54 (1H, td, J 12.6 
and 2.6), 3.01 (1H, app.t), 3.54 (1H, dd, J 12.3 and 4.6), 3.61-3.64 (1H, m), 4.13 (1H, d, J 14.1), 4.17 (1H, d, J 
14.1), 4.19 (1H, d, J 15.9), 4.24 (1H; tt, J 12.0 and 4.1), 4.40 (1H, d, J 15.9), 7.11 (1H, d, J 8.7, Ar), 7.14 (1H, dd, 
J 8.7 and 1.8, Ar), 7.18-7.23 (3H, m, Ar), 7.27-7.30 (3H, m, Ar), 7.32-7.37 (4H, m, Ar), 7.72 (1H, d, J 1.8, Ar); 
LC-MS (ESI+) m/z = 480.3 [M+H]+. 
General Procedure E: Benzimidazole Intermediate Synthesis (20) 
A mixture 18 (0.3g, 1.41 mmol), sodium dithionite (0.67g, 3.84 mmol) and 19 (1.0 eq.) in methanol (16 mL) 
and water (4 mL) was heated by microwave for 10 mins at 100 oC, then diluted with ethyl acetate (20 mL), 
washed with water (20 mL) and brine (20 mL), dried (MgSO4) and evaporatated. Recrystallisation from ethyl 
acetate, petrol gave 20. 
 General Procedure F: Boc deprotection (21) 
A mixture of 20 (0.40 g, 0.94 mmol ), TFA (0.6 mL) and DCM (2 mL) was stirred at rt for 4.5 h, then 
concentrated and diluted with methanol (4 mL). K2CO3 (0.2 g) was added and the suspension was stirred at 
rt, then filtered, and concentrated. Chromatography (5% DCM, MeOH) gave 21. Intermediates 21{2},21{3}, 
21{4} were used directly in the subsequent step without purification. 
General Procedure G: Benzimidazole Synthesis (9) 
21 (0.01 g, 0.028 mmol) was added to a solution of the appropriate isocyanate (1.2 eq.) in DCM (2 mL) and 
the mixture was stirred at rt for 1 h, then concentrated. Chromatography (NH-silica; 2% MeOH, DCM) gave 9 
as glassy solids. 
N-(4-Acetylphenyl)-4-(6-chloro-1-(3-chlorobenzyl)-1H-benzo[d]imidazole-2-yl)piperidine-1-carboxamide 
9{2,2} 
General Procedure G: 21{2} (0.011 g, 0.029mmol), 4-acetylphenylisocyanate (0.005 g, 0.032 mmol). 9{2,2} 
81%; HPLC purity (as area %) > 99; 1H NMR (400 MHz ,CDCl3) 1.88 (m, 2H, CH2CH), 2.09 (m, 2H, CH2NCO), 
2.49, (s, 3H, COCH3) 2.99 (m, 2H, CH2NCO), 3.07(m, 1H, CH2CH), 4.17 (m, 2H, CH2CH2NCO), 5.31 (s, 2H, 
CH2Ar), 6.49 (s, 1H, N-H), 6.85 (m, 1H, Ar-H), 7.06 (s, 1H, Ar-H), 7.14 (d, 2H, J 8.37 Hz, Ar-H) 7.17 (d, 1H, J 1.82 
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Hz, Ar-H), 7.39 (d, 3H, J 7.91 Hz Ar-H), 7.38 (d, 2H, J 8.85 Hz, Ar-H), 7.81 (d, 1H, J 8.56 Hz, Ar-H); LC-MS (ESI+) 
m/z = 519 [M+H]+. 
4-(6-Chloro-1-(3-chlorobenzyl)-1H-benzo[d]imidazol-2-yl)-N-(3,4,5-trimethoxyphenyl)piperidine-1-
carboxamide 9{2,3} 
General Procedure G: 21{2} (0.05 g, 0.14 mmol), 3,4,5-trimethoxyphenylisocyanate (0.035 g, 0.16 mmol). 
9{2,3} 73 %; HPLC purity (as area %) > 92; 1H NMR (400 MHz ,CDCl3) 1.82 (m, br, 2H, CH2CH2-NH), 2.10 (m, 
2H, CH2CH2-NH), 2.99 (m, 3H, CH2-CH2-NH, CH-CH2), 3.73 (s, 3H, Ar-OMe), 3.77 (s, 6H, Ar-(OMe)2), 4.12 (m, 
2H, CH2-N), 5.27 (s, 2H, CH2-N), 6.31 (s, 1H, N-H), 6.59 (s, 2H, Ar-H), 6.72 (d,1H, J 7.21, Ar-H), 7.01 (s, 1H, Ar-
H), 7.13 (m, 3H, Ar-H), 7.62 (d, 1H, 8.33 Hz, Ar-H); LC-MS (ESI+) m/z 569 [M+H]+;  
Ethyl-4-(4-(6-chloro-1-(3-chlorobenzyl)-1H-benzo[d]imidazole-2-yl)piperidine-1-carboxamido) benzoate 
9{2,8}  
General Procedure G: 21{2} (0.011 g, 0.029 mmol), ethyl 4-isocyanobenzoate (0.006 g, 0.032 mmol). 9{2,8} 
80%; HPLC purity (as area %) > 98; 1H NMR (400 MHz ,CDCl3) 1.40 (t, 3H, 7.11 Hz, OCH2CH3), 1.89 (m, 2H, 
CH2CH), 2.05 (m, 2H, CH2NCO), 3.04 (m, 2H, CH2NCO), 3.08 (m, 1H, CH2CH), 4.19 (m, 2H, CH2CH2NCO), 4.37 
(q, 2H, J 7.12 Hz OCH2CH3), 5.35 (s, 2H, CH2Ar), 6.58 (s, 1H, N-H), 6.85 (m, 1H, Ar-H), 7.06 (s, 1H, Ar-H), 7.21 
(d, 1H, J 1.82 Hz, Ar-H), 7.38 (m, 3H, Ar-H), 7.43 (d, 2H, J 8.83 Hz, Ar-H), 7.69 (d, 1H, J 8.56 Hz, Ar-H), 7.97 (d, 
2H, J 8.77 Hz, Ar-H; LC-MS (ESI+) m/z = 549 [M+H]+.  
N-(4-Acetylphenyl)-4-(6-chloro-1-(4-methoxybenzyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxamide 
9{4,2} 
General Procedure G: 21{4} (0.097 g, 0.27 mmol), 4-acetylphenylisocyanate (0.074 g, 0.46 mmol). 
Chromatography (50% EtOAc, petrol), 9{4,2} 55 %; HPLC purity (as area %) > 96; 1H NMR (400 MHz ,CDCl3) 
1.82 (m, 2H, CH2CH2-NH), 2.05 (m, 2H, CH2CH2-NH), 2.48(s, 3H, Ar-COCH3) 2.94 (m, 3H, CH2-CH2-NH and CH-
CH2), 3.71 (s, 3H, Ar-OMe), 4.12 (m, br 2H, CH2-N), 5.22 (s, 2H, CH2-N), 6.62 (s, 1H, N-H), 6.79 (d, 2H, J 8.7, Ar-
H), 6.84 (d, 2H, J 8.7, Ar-H), 7.18 (m, 2H, Ar-H), 7.39 (d, 2H, J 8.8, Ar-H), 7.6 (dd, 1H, J 8.1, 1.04, Ar-H), 7.89 (d, 
2H, J 8.8, Ar-H).; LC-MS (ESI+) m/z 517 [M+H]+.  
RESULTS 
Design 
The search for MDM2–p53 inhibitors has revealed several classes of small molecules able to bind MDM2 at 
the p53 binding site and restore p53 activity.(21) Reflecting the hydrophobic nature of the MDM2-p53 
interaction, all of these compounds are characterized by a central scaffold that directs hydrophobic 
substituents towards the three MDM2 sub-pockets, thus mimicking the key amino acid side-chains of p53. 
In an attempt to identify novel chemotypes acting as an anchor point for hydrophobic substituents, our 
attention was focused on compounds 1 and 7, taken as representative of two potent and structurally 
different classes of MDM2 inhibitors. The scaffold-hopping approach initially matched the two nitrogens of 
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the Nutlin imidazoline ring 1  with the two nitrogens in the benzimidazole scaffold (Figure 2, red). Overlay of 
the Nutlin chlorophenyl rings with the benzimidazole gave two possible orientations of the chloro group in 
the scaffold (8 and 9). Positions 1 and 2 of the benzimidazole ring were used to append the hydrophobic 
piperidinyl amide substituents judged to be necessary for activity, resulting in two different substitution 
patterns, represented by general structures 8 and 9 (Figure 2).  
<figure 2> 
Docking experiments showed two separate binding modes for the enantiomers of 8{1,6}. In the case of the 
(R)-enantiomer the chlorobenzimidazole occupies the Phe19 pocket and the aryl urea fills the Leu26 pocket, 
whereas for the (S)-enantiomer the positions are reversed (Figures 3a and 3b, respectively). The docked pose 
for 9{1,6} shows the arylurea occupying the Leu26 pocket and the benzyl group positioned within the Phe19 
pocket (Figure 3c). Interestingly, the Trp23 subpocket is unoccupied for all of the binding modes generated. 
This pocket is known to be important from the published X-ray structures of small-molecule MDM2-p53 
inhibitors. The other subpockets (Phe19 and Leu26) were occupied by the hydrophobic moieties of the 
ligands, thus rendering both libraries 8 and 9 worthy of exploration. For the alternative benzimidazoles 8, 
the (S)-enantiomers appeared to be more promising than (R)-enantiomers and therefore were prioritized for 
synthesis. 
<figure 3a,b,c> 
Synthesis    
The rapid synthesis of benzimidazole libraries has been described recently using a number of approaches, 
including solid-phase synthesis,(43, 44) and solution-phase methods.(45-48) In this case, the required N1-
substitution was introduced via an SNAr reaction with an o-fluoronitrobenzene, followed by in-situ nitro-
reduction, using sodium dithionite under microwave heating, and cyclisation with the desired aldehyde to 
give the the appropriately substituted benzimidazoles 8 and 20.(49)                                                                                        
The synthesis of benzimidazoles 8 bearing substituted aryl groups required the use of suitably substituted 
arylacetaldehydes (10). These were prepared from the respective benzaldehydes using a Wittig reaction 
giving the methyl enol ethers (11), which were subjected to acidic hydrolysis (Scheme 1). The SNAr reaction 
of (S)-12 and 4-chloro-1-fluoro-2-nitrobenzene gave nitroaniline (13) in good yield. Reductive cyclisation of 
13 with sodium dithionite in the presence of arylacetaldehydes 10, under microwave heating, provided 
benzimidazoles 14{1-4} cleanly and in good yields. Deprotection with TFA gave piperidines 15{1-4} which 
were reacted in parallel with a series of isocyanates to give the final (S)-benzimidazoles 8{1-4,1-10} (Scheme 
2). Single examples of the thiourea 16 and sulfonamide 17 derivatives were also prepared (Scheme 3). 
The synthesis of 2-(piperidin-4-yl)-benzimidazoles 9 required the Boc-protected isonipecotic aldehyde (18), 
prepared according to a literature procedure (Scheme 4).(50) 
<scheme 1,2,3,4, Chemsets> 
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Reaction of 4-chloro-1-fluoro-2-nitrobenzene with the required benzylamine under microwave heating gave 
nitroanilines (19). Reductive cyclisation of 19 with sodium dithionite in the presence of aldehydes 14, under 
microwave heating gave the benzimidazoles 20{1-4} in good yields. Deprotection with TFA gave piperidines 
21{1-4} which were reacted in parallel with a series of isocyanates giving the final benzimidazoles 9{1-4,1-10} 
(Scheme 5).  
<scheme 5> 
Biological evaluation 
We have previously demonstrated that the MDM2 and MDMX ELISA assays show good sensitivity over a 
wide range of IC50 values. In particular, compounds with low potency and poor predicted solubility have 
given reliable results.(40, 41) Compounds from libraries 8 and 9 were assayed against MDM2 and MDMX in 
parallel. The results are displayed in Tables 1 and 2. Overall, both series displayed limited MDM2 inhibition 
with only 8{4,7}, and 9{2,8} showing sub-100 M activity (MDM2 LE = 0.14 and 0.15, respectively). In 
contrast, 27/40 examples of series 8 were sub-100 M inhibitors of MDMX, and two examples showed sub-
50 M activity, i.e. 8{3,4} and 8{4,7} (MDMX LE = 0.15). Series 9 also had a greater number of sub-100 M 
MDMX inhibitors (10/30), and four examples showed sub-50 M activity, i.e. 9{2,2}, 9{2,3},9{2,8} and 9{4,2} 
(MDMX LE = 0.15 - 0.16). Interestingly, the unsubstituted thiourea derivative 16 and the sulfonamide 17 
showed improved MDMX inhibitory activity when compared with the equivalent urea 15{1,6}. 
<table 1, 2> 
<structure 8{3,4}, 8{4,7}, 9{2,8},9{2,2}, 9{2,3}, 9{2,8}, 9{4,2}> 
DISCUSSION 
Recently, analysis of the contribution to binding of each portion of Nutlin-3 (1) has been reported, by the 
synthesis and analysis of fragments of the lead compound.(51) Systematic removal of the groups accessing 
each of the three sub-pockets of MDM2 allowed an assessment of their relative contribution to binding, and 
showed that removal of the 4-chlorophenyl group accessing the Trp23 pocket resulted in the most 
significant loss of activity. For example, 22 showed a Kd for MDM2 of 1 mM (LE = 0.10). The activity of 
libraries 8 and 9 are consistent with the loss of potency associated with leaving the Trp23 sub-pocket vacant 
as predicted in the docked binding modes of both series. Interestingly, the results for MDMX suggest that 
the Trp23 sub-pocket may play a somewhat less significant role in the overall binding affinity, as libraries 8 





Libraries of substituted benzimidazoles based on scaffold-hopping from structures 1 and 7 have been docked 
into MDM2 and evaluated. The efficient synthesis of two libraries (8 and 9) has been achieved by 
microwave-assisted reductive cyclisation. Both libraries were assayed for inhibition of the MDM2-p53 and 
MDMX-p53 protein-protein interaction. Members of each library showed sub-100 M activity for MDM2 or 
MDMX and several mixed MDM2-MDMX inhibitors were identified with modest potency. 
SUPPORTING INFORMATION 
Synthetic and analytical details for  compounds 8, 13, 14, 15, 16, 19, 20, 21. 
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Table 1. MDM2-p53 and MDMX-p53 inhibitory activity of compound libraries 13 and 8. 




Chart 1: MDM2-p53 clinical trials candidates with disclosed structures. 
Figure 1: Structure of the p53-MDM2 complex (1RV1) (MDM2 white, p53 peptide yellow).(15) 
Figure 2: Schematic for scaffold hopping and docking approach. 




Scheme 1: Synthesis of substituted phenylacetaldehydes 10.a 
a Reagents and Conditions: a) MeOCH2PPh3Br, KOt-Bu, THF, rt; b) HCO2H, DCM, rt. 
Scheme 2: Synthesis of benzimidazole library 8.a 
a Reagents and Conditions: a) DMF, Na2CO3, 70 oC; b) ArCH2CHO, 13, Na2S2O4, MeOH, H2O, MW, 100 oC; c)i) 
TFA, DCM, rt; ii) K2CO3, MeOH, rt; d) R’NCO, DCM, rt.  
Scheme 3: Synthesis of benzimidazoles 16 and 17.a 
a Reagents and Conditions: a) R’NCS, DCM, rt; b) PhCH2SO2Cl, Et3N, DCM, rt. 
Scheme 4: Synthesis of piperidine 18.a 
a Reagents and Conditions: a) Boc2O, NaOH, dioxane, rt; b) BH3-THF, THF, rt; c) PCC, NaOAc, 4Å molecular 
sieves, DCM, rt. 
Scheme 5: Synthesis of benzimidazole library 9.a 
a Reagents and Conditions: a) ArNH2, K2CO3, EtOH, rt; b) 19, Na2S2O4, MeOH, H2O, MW, 100 oC; c) i)TFA, DCM, 















13{1} >500 248 8{3,1} 170 64 ± 20 
13{2} 290 ± 38 104 ± 23 8{3,2} - - 
13{3} >500 >500 8{3,3} 121 ± 40 92 ± 18 
13{4} 211 130 8{3,4} 120 ± 37 43 ± 15 
8{1,1} 183 ± 20 70 ± 19 8{3,5} 213 ± 158 74 ± 12 
8{1,2} 208 ± 33 105 ± 54 8{3,6} 191 187 
8{1,3} 202 ± 24 54 ± 14 8{3,7} 146 ± 63 77 ± 20 
8{1,4} 176 117 8{3,8} >500 116 
8{1,5} 202 ± 51 92 ± 51 8{3,9} 257 ± 146 131 ± 48 
8{1,6} 218 100 8{3,10} 177 100 
8{1,7} 203 ± 80 61 ± 30 8{4,1} - - 
8{1,8} 196 ± 61 69 ± 5 8{4,2} 201 ± 96 95 ± 13 
8{1,9} >500 156 8{4,3} 115 207 
8{1,10} 257 169 8{4,4} 166 ± 55 78 ± 16 
8{2,1} 151 86 8{4,5} 188 ± 102 173 ± 121 
8{2,2} 134 ± 86 81 ± 33 8{4,6} 188 ± 33 109 ± 39 
8{2,3} 148 ± 61 60 ± 10 8{4,7} 72 ± 20 43 ± 24 
8{2,4} 201 ± 128 154 ± 79 8{4,8} 202 ± 157 76 ± 24 
8{2,5} 114 ± 38 80 ± 13 8{4,9} 198 ± 75 99 ± 26 
8{2,6} 125 ± 35 83 ± 29 8{4,10} 131 ± 45 64 ± 13 
8{2,7} 154 ± 81 57 ± 14 16 144 ± 44 49 ± 14 
8{2,8} 153 ± 112 50 ± 6 17 212 ± 1 59 ± 36 
8{2,9} 165 ± 30 73 ± 14    













20{1} 253 >500 9{2,9} - - 
20{2} 248 217 9{2,10} 212 101 
20{3} >500 >500 9{3,1} - - 
20{4} >500 >500 9{3,2} 201 103 
21{1} 282 >500 9{3,3} 182 ± 21 81 ± 20 
9{1,1} - - 9{3,4} 291 ± 117 252 ± 136 
9{1,2} 307 ± 132 154 ± 70 9{3,5} 183 >500 
9{1,3} 256 ± 51 94 ± 37 9{3,6} 269 ± 39 200 ± 100 
9{1,4} 141 ± 22 98 ± 62 9{3,7} >500 >500 
9{1,5} >500 151 9{3,8} 149 ± 61 94 ± 38 
9{1,6} >500 231 9{3,9} 218 123 
9{1,7} >500 194 9{3,10} 218 201 
9{1,8} 151 194 9{4,1} >500 >500 
9{1,9} >500 >500 9{4,2} 314 ± 65 49 ± 22 
9{1,10} 204 ± 69 111 ± 63 9{4,3} >500 145 
9{2,1} - - 9{4,4} - - 
9{2,2} 130 ± 65 46 ± 11 9{4,5} - - 
9{2,3} 243 45 9{4,6} >500 245 
9{2,4} 156 ± 40 113 ± 74 9{4,7} - - 
9{2,5} - - 9{4,8} 180 ± 15 73 ± 16 
9{2,6} - - 9{4,9} - - 
9{2,7} 161 ± 68 68 ± 29 9{4,10} >500 184 
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Reagents were purchased from fine chemicals vendors, and used as received unless otherwise stated. Solvents were 
purified and stored according to standard procedures. Petrol refers to that fraction in the boiling range 40-60 °C. THF 
refers to anhydrous tetrahydrofuran from commercial sources. Microwave reactions were performed using a Biotage 
Initiator instrument in sealed glass tubes. Melting points were obtained on a Stuart Scientific SMP3 apparatus and 
are uncorrected. Thin layer chromatography was performed using silica gel plates (Kieselgel 60F254; 0.2 mm), and 
visualized with UV light or potassium permanganate. Chromatography was conducted under medium pressure in 
glass columns or using a Biotage SP4 instrument in prepacked columns (FLASH+ Silica columns (40-63 µm, 60 Å). 
Proton (1H) and carbon (13C) nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Spectrospin AC 
300E (1H at 300 MHz, 13C at 75 MHz), a Jeol JNM-LA500 spectrometer (1H at 500 MHz, 13C at 125 MHz), or a Bruker 
Avance II 500 (1H at 500 MHz, 13C at 125 MHz) employing the solvent as internal standard. IR spectra were recorded 
on a Bio-Rad FTS 3000MX diamond ATR. Liquid Chromatography-Mass Spectrometry (LCMS) was carried out on a 
Micromass Platform instrument operating in positive and negative ion electrospray mode, employing a 50 x 4.6 mm 
C18 column (Waters Symmetry or Waters Atlantis) 5 or 12 min gradient elution with 0.05% formic acid in methanol 
(10-90%). Accurate masses were measured using a Finnigan MAR 95 XP or a Finnigan MAR 900 XLT at the EPSRC 
National Mass Spectrometry Service Centre (Chemistry Department, University of Wales, Swansea, Wales, SA2 8PP). 
tert-Butyl 3-((4-chloro-2-nitrophenyl)amino)piperidine-1-carboxylate (13)  
1,1-Dimethylethyl-3-aminopiperidine-1-carboxylate (1.29 g, 6.44 mmol) was added to a suspension of Na2CO3 (0.819 
g, 7.73 mmol) and 4-chloro-1-fluoro-2-nitrobenzene (1.13 g, 6.44 mmol) in dry DMF (20 mL), and stirred at 70 oC for 
2.5 hours. The mixture was diluted with water (200 mL) and extracted with ethyl acetate (3 x 70 mL). The combined 
organic layers were washed with water (2 x 50 mL), brine (50 mL), and dried (MgSO4), and evaporated. 
Chromatography (silica; 0-20% ethyl acetate, petrol) gave 13 as a bright orange oil (1.80 g, 79%). 1H NMR (400 MHz, 
CD3CN) δ 1.34 (br s, 9H), 1.51-1.62 (1H, br m), 1.64 - 1.83 (2H, br m), 1.92 – 1.99 (1H, m), 3.27 – 3.53 (3H, br m), 3.54 
– 3.66 (1H, br m), 3.69 – 3.76 (1H, m), 7.05 (1H, d, J 9.3, Ar), 7.47 (1H, dd, J 2.5 and 9.3, Ar), 8.07 (1H, d, J 6.7, NH), 
8.11 (1H, d, J 2.5, Ar); 13C NMR (125 MHz, CD3CN) 23.0, 28.4, 30.0, 44.3, 45.3, 48.5, 48.9, 80.2, 117.5, 120.4, 126.5, 
132.9, 137.2, 144.4, 155.4; HRMS C16H26Cl2O4N4Cl [M+NH4]+ calcd 373.1637, obsd 373.1642. 
Chemical Synthesis. 
General Procedure A – Synthesis of compounds (14). 
 A mixture of the appropriate aldehyde (1.2 eq.), sodium dithionite (86% purity; 1.98 g, 9.78 mmol, 3 eq.) and 13 
(1.16 g, 3.26 mmol, 1.0 eq.) in methanol (12 mL) and water (3 mL) was heated in a microwave reactor for 10 minutes 
at 100 oC. The sample was diluted with ethyl acetate (20 mL) and washed with water (20 mL) and brine (20 mL). The 
organic layer was dried (MgSO4), and evaporated. Chromatography (silica; ethyl acetate, petrol) gave compound 14. 
(S)-tert-Butyl 3-(2-benzyl-5-chloro-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxylate 14{1}. 
General Procedure A: phenylacetaldehyde (0.42 mL, 3.59 mmol). 14{1} (0.94 g, 61%), pale pink solid; HPLC purity (as 
area %) > 99; 1H NMR (400 MHz, CDCl3) δ 1.43 (br.s., 12H), 1.71(1H, d, J  12.4), 2.09 (1H, qd, J  3.7 and 12.8), 2.65 (1H, 
app.), 3.29 (1H, app.t), 4.13-4.21 (2H, m), 4.25 (1H, d, J  15.6), 4.41 (1H, br. d, J  15.6), 7.16 (1H, dd, J  1.8 and 8.7, Ar), 
7.18-7.30 (5H, m, Ar), 7.34 (1H, d, J  8.7, Ar), 7.74 (1H, d, J  1.8, Ar); 13C NMR (125 MHz, CDCl3) 24.9, 28.4, 28.8, 35.3, 
43.6, 46.8, 53.7, 80.4, 112.4, 119.9, 122.6, 127.3, 127.6, 128.4, 129.0, 132.4, 136.1, 144.3, 154.4, 154.7. 
(S)- tert-Butyl-3-(5-chloro-2-(3-chlorobenzyl)-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxylate 14{2}.  
General Procedure A: 2-(3-chlorophenyl) acetaldehyde (0.604 g, 3.91 mmol). 14{2} (0.76 g, 51%), off-white solid; mp 
64-65 oC; HPLC purity (as area %) > 97; IR (cm-1) 2974, 2928, 2872, 1686, 1510, 1467, 1453, 1435, 1414, 1404, 1391, 
1365, 1256, 1238, 1142, 1063, 994, 910, 884, 857, 792, 769, 684; 1H NMR (500 MHz, CDCl3) δ 1.38 (br.s., 11H), 1.70 
(2H, app.d), 2.09 (1H, qd, J  4.0 and 12.8), 2.63 (1H, app.t), 3.25 (1H, br s), 4.04-4.11 (2H, m), 4.17 (1H, d, J  16.0), 4.32 
(1H, br. d, J  16.0), 7.00-7.02 (1H, m, Ar), 7.12 (1H, dd, J  1.9 and 8.7, Ar), 7.15-7.17 (3H, m, Ar), 7.30 (1H, d, J  8.7, Ar), 
7.68 (1H, d, J 1.9, Ar); 13C NMR (125 MHz, CDCl3) 25.0, 28.4, 28.9, 34.7, 43.6, 46.8, 53.7, 80.4, 112.4, 120.0, 122.8, 
126.5, 127.5, 127.7, 128.4, 130.2, 132.3, 134.9, 138.1, 144.2, 153.5; HRMS C24H27Cl2N3O2 [M+H]+ calcd 460.1553, 
obsd 460.1552. 
(S)-tert-Butyl-3-(5-chloro-2-(3-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxylate 14{3}.  
General Procedure A: 2-(3-methoxyphenyl) acetaldehyde (0.588 g, 3.91 mmol) gave 14{3} (0.66 g, 44%) as a pinkish 
solid; mp 62-63 oC; HPLC purity (as area %) > 99; IR (cm-1) 3000, 2973, 2931, 2862, 1686, 1599, 1585, 1490, 1454, 
1435, 1404, 1365, 1256, 1283, 1143, 1044, 908, 881, 855, 794, 768; 1H NMR (500 MHz, CDCl3) δ 1.43 (br.s., 11H), 
1.71(2H, app.d), 2.05 (1H, qd, J  3.6 and 12.6), 2.60 (1H, app.t), 3.25 (1H, br s), 3.66 (3H, s, OCH3), 4.11-4.17 (3H, m), 
4.16 (1H, d, J  15.8), 4.32 (1H, br. d, J  15.8), 6.67-6.71 (3H, m, Ar), 7.09 (1H, dd, J  1.9 and 8.7, Ar), 7.12-7.15 (1H, m, 
Ar), 7.29 (1H, d, J  8.7, Ar), 7.67 (1H, d, J  1.9, Ar); 13C NMR (125 MHz, CDCl3) 25.0, 28.4, 28.8, 35.2, 43.6, 46.8, 53.6, 
55.2, 80.3, 112.3, 112.7, 114.0, 119.9, 120.6, 122.5, 127.6, 129.9, 132.3, 137.6, 144.2, 154.2, 154.7, 160.0; HRMS 
C25H3035ClN3O3 [M+H]+ calcd 456.2048, obsd 456.2053. 
 (S)- tert-Butyl 3-(5-chloro-2-(4-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxylate 14{4}. 
General Procedure A: 2-(4-methoxyphenyl) acetaldehyde (0.588 g, 3.91 mmol). 14{4} (0.40 g, 27%), off-white solid; 
mp 60-61 oC; HPLC purity (as area %) > 99; IR (cm-1) 2969, 2933, 2868, 2836, 1689, 1612, 1511, 1454, 1418, 1404, 
1389, 1366, 1303, 1242, 1176, 1142, 1107, 1063, 1032, 923, 901, 885, 857, 819, 793, 775, 765, 733; 1H NMR δ (500 
MHz, CDCl3) δ 1.47 (br.s., 11H), 1.77 (2H, app.d), 2.14 (1H, qd, J  3.6 and 12.7), 2.70 (1H, app.t), 3.33 (1H, br s), 3.79 
(3H, s, OCH3), 4.10-4.25 (3H, m), 4.36 (1H, br. d, J  15.7), 6.84 (2H, d, J  8.7, Ar), 7.13 (1H, d, J  8.7, Ar), 7.19 (1H, dd, J  
1.9 and 8.7, Ar), 7.38 (1H, d, J  8.7, Ar), 7.67 (1H, d, J  1.9, Ar); 13C NMR (125 MHz, CDCl3) 25.0, 28.3, 28.8, 34.3, 43.6, 
46.8, 53.6, 55.2, 80.3, 112.4, 114.4, 119.8, 122.5, 127.5, 128.0, 129.3, 132.4, 144.2, 154.7, 158.7; HRMS C25H30ClN3O3 
[M+H]+ calcd 456.2048, obsd 456.2046. 
 
General Procedure B. Compound 14 was dissolved in DCM (2 mL) and TFA (3 mL) and the mixture stirred at rt for 1 
hour, then evaporated. The residue was diluted with DCM (20 mL) and neutralised with sodium carbonate (sat.; 20 
mL). The organic layer was dried (MgSO4) to give 15 which was used without further purification.  
(S)-2-Benzyl-5-chloro-1-(piperidin-3-yl)-1H-benzo[d]imidazole 15{1}. 
General Procedure B: 14{1} (0.725 g, 1.575 mmol). 15{1} (0.53 g, 94%), white solid; 1H NMR (500 MHz ,CDCl3) 1.42 
(1H, qt, J 4.0 and 12.9), 1.54 (1H, app.d), 1.67 (1H, br s, NH), 1.73-1.77 (1H, m), 2.12 (1H, qd, J  4.2 and 12.8), 2.57 
(1H, td, J  = 2.5 and 12.4), 2.79 (1H, dd, J 3.7 and 11.4), 3.02(1H, br d), 3.23 (1H, t, J 11.4), 4.20-4.26 (1H, m), 4.31 (1H, 
d, J 15.7, -CHHAr), 4.37 (1H, d, J 15.7, -CHHAr), 7.16 (1H, dd, J 2.0 and 8.6, Ar), 7.21-7.31 (5H, m, Ar), 7.42 (1H, d, J 
8.6, Ar); 7.73 (1H, d, J 2.0, Ar); 13C NMR (125 MHz, CDCl3) 26.5, 29.2, 35.2, 45.9, 49.6, 55.3, 112.6, 119.6, 122.3, 127.1, 
127.3, 128.3, 128.8, 132.5, 136.2, 144.2, 154.4;  
 (S)-5-Chloro-2-(3-chlorobenzyl)-1-(piperidin-3-yl)-1H-benzo[d]imidazole 15{2}. 
General Procedure B: 14{2} (0.725 g, 1.575 mmol). 15{2} (0.53 g, 94%), white solid; 1H NMR (500 MHz ,CDCl3) 1.46 
(1H, qt, J 4.0 and 12.9), 1.57 (1H, app.d), 1.75 (1H, br s, NH), 1.76-1.81 (1H, m), 2.14 (1H, qd, J 4.1 and 12.7), 2.59 (1H, 
td, J 2.6 and 12.4), 2.88 (1H, dd, J 3.6 and 11.5), 3.04-3.06 (1H, m), 3.27 (1H, t, J 11.5), 4.17-4.23 (1H, m), 4.27 (1H, d, 
J 16.0, -CHHAr), 4.35 (1H, d, J 16.0, -CHHAr), 7.09-7.12 (1H, m, Ar), 7.17 (1H, dd, J 2.0 and 8.7, Ar), 7.22-7.23 (3H, m, 
Ar), 7.44 (1H, d, J 8.7, Ar); 7.73 (1H, d, J 2.0, Ar); 13C NMR (125 MHz, CDCl3) 26.4, 29.4, 34.7, 45.9, 49.7, 55.3, 112.7, 
119.7, 122.5, 126.5, 127.4, 127.5, 128.4, 130.1, 132.5, 134.7, 138.2, 144.1, 153.5; HRMS C19H20N335Cl2 [M+H]+ calcd 
360.1029, obsd 360.1028. 
(S)-5-Chloro-2-(3-methoxybenzyl)-1-(piperidin-3-yl)-1H-benzo[d]imidazole 15{3}. 
General Procedure B: 14{3} (0.514 g, 1.127 mmol). 15{3} (0.38 g, 95%), white solid; 1H NMR (500 MHz ,CDCl3) 1.45 
(1H, qt, J 4.0 and 13.0), 1.58 (1H, app.d), 1.64 (1H, br s, NH), 1.75-1.79 (1H, m), 2.13 (1H, qt, J 4.2 and 12.8), 2.58 (1H, 
td, J 2.6 and 12.3), 2.83 (1H, dd, J 3.7 and 11.6), 3.02-3.05 (1H, m), 3.24 (1H, t, J 11.4), 3.74 (3H, s, OCH3), 4.22-4.28 
(1H, m), 4.28 (1H, d, J 15.9, -CHHAr), 4.34 (1H, d, J 15.8, -CHHAr), 6.76-6.78 (2H, m, Ar), 6.80-6.82 (1H, m, Ar), 7.16 
(1H, dd, J 2.0 and 8.8, Ar), 7.19-7.23 (1H, m, Ar), 7.42 (1H, d, J 8.8, Ar), 7.72 (1H, d, J 2.0); 13C NMR (125 MHz, CDCl3) 
26.3, 29.2, 35.2, 45.8, 49.4, 55.0, 55.3, 112.6, 112.6, 114.0, 119.7, 120.7, 122.3, 127.3, 129.8, 132.5, 137.7, 144.2, 
154.3, 160.0; HRMS C20H23N3O35Cl [M+H]+ calcd 356.1524, obsd 356.1526. 
(S)-5-Chloro-2-(4-methoxybenzyl)-1-(piperidin-3-yl)-1H-benzo[d]imidazole 15{4}. 
General Procedure B: 14{4} (0.376 g, 0.825 mmol). 15{4} (0.29 g, 99%), white solid; 1H NMR (500 MHz ,CDCl3) 1.45 
(1H, qt, J 4.0 and 12.9, 15-Hax), 1.58 (1H, app.d, 14-Heq), 1.76-1.80 (2H, m, 15-Heq and NH), 2.13 (1H, qd, J 4.1 and 
12.7, 14-Hax), 2.58 (1H, td, J 2.6 and 12.4, 16-Hax), 2.80 (1H, dd, J 3.8 and 11.6, 12-Heq), 3.02-3.06 (1H, m, 16-Heq), 3.23 
(1H, t, J 11.5, 12-Hax), 3.77 (3H, s, OCH3), 4.21-4.27 (1H, m, 13-Hax), 4.24 (1H, d, J 15.8, -CHHAr), 4.29 (1H, d, J 15.8, -
CHHAr), 6.82 (2H, d, J 8.8, 2 x 10-H), 7.14 (2H, d, J 8.8, 2 x 9-H), 7.15 (1H, dd, J 2.0 and 8.8, 5-H), 7.42 (1H, d, J 8.8, 6-
H); 7.72 (1H, d, J 2.0, 3-H); 13C NMR (125 MHz, CDCl3) 26.6 (C-15), 29.3 (C-14), 34.3 (CH2), 46.0 (C-16), 49.6 (C-12), 
55.3 (OCH3 and C-13), 112.6 (C-6), 114.2 (C-10), 119.6 (C-3), 122.2 (C-5), 127.2 (C-4), 128.2 (C-8), 129.4 (C-9), 132.5 
(C-7), 144.2 (C-2), 154.8 (C-1), 158.6 (C-11); HRMS for C20H23N3O35Cl [M+H]+ calcd 356.1524, obsd 356.1521. 
 
General procedure C. Either an aliquot of a solution of 15 in dry DCM (1 mL, 0.049 M), or weighed 15 in dry DCM (1 
mL) was treated with the named isocyanate (1.5 eq.). The mixture was quenched with NH2-silica and filtered through 
a plug of NH2-silica. Evaporation gave 8 without further purification.  
(S)-3-(5-Chloro-2-benzyl-1H-benzo[d]imidazol-1-yl)-N-(4-nitrophenyl)piperidine-1-carboxamide 8{1,1}. 
General procedure C: 15{2} (29 mg, 89 µmol) and 4-nitrophenyl isocyanate (22 mg, 134 µmol). 8{1,1} (31 mg, 71%), 
yellow solid; HPLC purity (as area %) > 97; 1H NMR (500 MHz, CDCl3) 1.43 (1H, qt, J 4.0 and 13.1), 1.58 (1H, app.d), 
1.80 (1H, app. d), 2.14 (1H, qd, J 4.1 and 12.8), 2.76 (1H, td, J 2.5 and 13.3), 3.37 (1H, t, J 12.2), 3.81 (1H, m), 4.17-
4.28 (4H, m), 7.04 (1H, app.t, Ar), 7.10-7.20 (4H, m, Ar), 7.21 (1H, s, NH), 7.29 (1H, d, J 8.7, Ar), 7.45 (2H, d, J 9.2, Ar), 
7.67 (1H, d, J 2.0, Ar), 8.07 (2H, d, J 9.2, Ar); 13C NMR (125 MHz, CDCl3) 24.9, 28.6, 35.2, 44.2, 47.2, 53.6, 112.2, 118.8, 
119.9, 122.8, 124.9, 127.4, 127.9, 128.4, 129.0, 132.2, 135.9, 142.6, 144.1, 145.5, 153.9, 154.4; MS (ESI+) m/z = 
490.3. HRMS calcd for C26H2435ClN5O3 [M + H]+ 490.1640, obsd 490.1627 
(S)-3-(5-Chloro-2-benzyl-1H-benzo[d]imidazol-1-yl)-N-(4-acetylphenyl)piperidine-1-carboxamide 8{1,2}. 
General procedure C: 15{1} (30 mg, 92 µmol) and 4-acetylphenyl isocyanate (22 mg, 138 µmol). 8{1,2} (27 mg, 60%), 
white solid; HPLC purity (as area %) > 96; 1H NMR (500 MHz, CDCl3) 1.53 (1H, qt, J 4.0 and 13.3), 1.72 (1H, app.d), 
1.88-1.91 (1H, m), 2.26 (1H, qd, J 4.1 and 12.8), 2.57 (3H, s, COCH3), 2.85 (1H, td, J 2.6 and 13.3), 3.42 (1H, app.t), 
3.68 (1H, dd, J 4.3 and 12.6), 4.16 (1H, app.d), 4.28-4.34 (2H, m), 4.38 (1H,d, J 15.9), 6.25 (1H, s, NH), 7.10 (1H, tt, J 
1.5 and 7.0, Ar), 7.19 (1H, dd, J 2.0 and 8.7, Ar), 7.20-7.27 (5H, m, Ar), 7.35-7.39 (3H, m, Ar), 7.76 (1H, d, J 2.0, Ar), 
7.92 (1H, d, J 8.8, Ar); 13C NMR (125 MHz, CDCl3) 24.9, 26.4, 28.6, 35.2, 44.3, 47.2, 53.5, 112.1, 118.7, 120.0, 122.8, 
127.4, 127.8, 128.4, 129.0, 129.7, 132.1, 132.2, 136.1, 143.2, 144.2, 154.0, 154.3, 196.9; MS (ESI+) m/z = 487.3 
[M+H]+; HRMS C19H20N335Cl2 [M+H]+ calcd 360.1029, obsd 360.1028. 
(S)-3-(5-Chloro-2-benzyl-1H-benzo[d]imidazol-1-yl)-N-(3,4,5-trimethoxyphenyl)piperidine-1-carboxamide 8{1,3}. 
General procedure C: 15{1} (27 mg, 83 µmol) and 3,4,5-(trimethoxy)phenyl isocyanate (26 mg, 126 µmol). 8{1,3} (16 
mg, 36%), white solid; HPLC purity (as area %) > 94; 1H NMR (500 MHz, CDCl3) 1.45 (1H, qt, J 4.0 and 13.2), 1.61 (1H, 
app.d), 1.80 (1H, app.d), 2.15 (1H, qd, J 4.0 and 12.8), 2.75 (1H, td, J 2.3 and 13.1), 3.32 (1H, t, J 12.1), 3.62-3.65 (1H, 
m), 3.74 (3H, s, OCH3), 3.77 (6H, s, 2 x OCH3), 4.06 (1H, app.d), 4.21-4.26 (1H, m), 4.28 (2H, s, CH2Ph), 5.96 (1H, s, 
NH), 6.52 (1H, s, Ar), 7.08 (1H, t, J 7.2, Ar), 7.12 (1H, dd, J 2.0 and 8.7, Ar), 7.15 (2H, app.d, Ar), 7.18-7.21 (2H, m, Ar), 
7.29 (1H, d, J 8.7, Ar), 7.69 (1H, d, J 2.0, Ar); 13C NMR (125 MHz, CDCl3) 24.9, 28.6, 35.2, 44.2, 47.3, 53.6, 56.1, 61.0, 
98.1, 112.2, 120.0, 122.7, 127.3, 127.8, 128.5, 129.0, 132.2, 134.3, 134.6, 136.1, 144.2, 153.3, 154.4, 154.9; MS (ESI+) 
m/z = 535.3 [M+H]+; HRMS for C29H3235ClN4O4 [M+H]+ calcd 535.2107, obsd 535.2104.  
(S)-3-(5-Chloro-2-benzyl-1H-benzo[d]imidazol-1-yl)-N-(4-trifluoromethoxyphenyl)piperidine-1-carboxamide 8{1,4}. 
General procedure C: 15{1} (1 mL, 49 µmol) and 4-(trifluoromethoxy)phenyl isocyanate (11 µl, 78 µmol). 8{1,4} (22 
mg, 82%), white solid; HPLC purity (as area %) > 96; 1H NMR (500 MHz, CDCl3) 1.50 (1H, qt, J 4.1 and 13.1), 1.67 (1H, 
app.d), 1.87 (1H, app.d), 2.22 (1H, qd, J 4.1 and 12.8), 2.81 (1H, td, J 2.6 and 13.2), 3.39 (1H, app.t), 3.71 (1H, dd, J 4.4 
and 12.7), 4.15 (1H, app.d), 4.25-4.34 (3H, m), 6.28 (1H, s, NH), 7.10-7.20 (6H, m, Ar), 7.23-7.26 (2H, m, Ar), 7.30 (2H, 
d, J 9.1, Ar), 7.35 (1H, d, J 8.7, Ar), 7.74 (1H, d, J 1.9, Ar); 13C NMR (125 MHz, CDCl3) 24.8, 28.6, 35.1, 44.2, 47.2, 53.5, 
112.2, 119.9, 120.5 (q, J 256.6), 121.3, 121.6, 122.8, 127.3, 127.8, 128.4, 129.0, 132.2, 136.0, 137.3, 144.1, 144.8, 
154.3, 154.6; 19F NMR (470.7 MHz, CDCl3) -58.14; MS (ESI+) m/z = 529.3 [M+H]+.  
(S)-3-(5-Chloro-2-benzyl-1H-benzo[d]imidazol-1-yl)-N-(4-trifluoromethylphenyl)piperidine-1-carboxamide 8{1,5}. 
General procedure C: 15{1} (26 mg, 80 µmol) and 4-(trifluoromethyl)phenyl isocyanate (11.2 µl, 78.4 µmol). 8{1,5} 
(20 mg, 79%), white solid; HPLC purity (as area %) > 97; 1H NMR (500 MHz, CDCl3) 1.52 (1H, qt, J 4.0 and 13.2), 1.69 
(1H, app.d), 1.88 (1H, app.d), 2.23 (1H, qd, J 4.1 and 12.8), 2.83 (1H, td, J 2.5 and 13.3), 3.40 (1H, app.t), 3.71 (1H, dd, 
J 4.3 and 12.6), 4.17 (1H, d, J 12.3), 4.26-4.33 (3H, m), 6.40 (1H, s, NH), 7.11 (1H, app.t, Ar), 7.18-7.20 (3H, m, Ar), 
7.24 (2H, app.t, Ar), 7.35 (1H, d, J 8.7, Ar), 7.41 (2H, d, J 8.6, Ar), 7.54 (2H, d, J 8.6, Ar), 7.75 (1H, d, J 2.0, Ar); 13C NMR 
(125 MHz, CDCl3) 24.9, 28.6, 35.2, 44.2, 47.2, 53.5, 112.2, 119.4, 119.9, 122.8, 126.2 (q, J 3.8), 127.4, 127.9, 128.4, 
129.0, 132.2, 136.0, 141.9, 144.1, 154.3, 154.3; 19F NMR (470.7 MHz, CDCl3) -61.9; MS (ESI+) m/z = 513.3 [M+H]+. 
 (S)-3-(5-Chloro-2-benzyl-1H-benzo[d]imidazol-1-yl)-N-phenylpiperidine-1-carboxamide 8{1,6}. 
General procedure C: 15{1} (1 mL, 49 µmol) and phenyl isocyanate (8 µl, 76 µmol). 8{1,6} (17 mg, 77%) as a white 
solid; HPLC purity (as area %) > 93; 1H NMR (500 MHz, CDCl3) 1.50 (1H, qt, J 4.1 and 13.1), 1.66 (1H, app.d), 1.83-1.87 
(1H, m), 2.23 (1H, qd, J 4.1 and 12.8), 2.82 (1H, td, J 2.6 and 13.3), 3.39 (1H, app.t), 3.72 (1H, dd, J 4.5 and 12.7), 4.11-
4.14 (1H, m), 4.31 (1H, dt, J 4.5 and 11.9), 4.34 (2H,s), 6.06 (1H, s, NH), 7.07 (1H, tt, J 1.6 and 7.0, Ar), 7.12 (1H, t, J 
7.2, Ar), 7.19 (1H, dd, J 2.1 and 8.7, Ar), 7.21-7.32 (8H, m, Ar), 7.37 (1H, d, J 8.7, Ar), 7.76 (1H, d, J 2.1, Ar); 13C NMR 
(125 MHz, CDCl3) 24.9, 28.6, 35.2, 44.3, 47.3, 53.5, 112.2, 119.9, 120.2, 122.7, 123.5, 127.3, 127.7, 128.4, 128.9, 
129.0, 132.2, 136.1, 138.5, 144.2, 154.4, 154.9; MS (ESI+) m/z = 445.3 [M+H]+; HRMS C26H2635ClN4O [M+H]+ calcd 
445.1790, obsd 445.1787. 
(S)-Ethyl 3-(3-(5-chloro-2-benzyl-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxamido)benzoate 8{1,7}.  
General procedure C: 15{1} (22 mg, 67.7 µmol) and ethyl 3-isocyanatobenzoate (19 mg, 101 µmol). 8{1,7} (17 mg, 
49%) as a white solid; HPLC purity (as area %) > 99; 1H NMR (500 MHz, CDCl3) 1.32 (3H, t, J 7.1, OCH2CH3), 1.46 (1H, 
qt, J 3.8 and 13.2), 1.63 (1H, app.d), 1.80 (1H, app.d), 2.18 (1H, qd, J 4.0 and 12.8), 2.76 (1H, td, J 2.5 and 13.2), 3.34 
(1H, t, J 12.1), 3.64 (1H, app d), 4.10 (1H, app d), 4.23-4.35 (5H, m), 6.12 (1H, s, NH), 7.08 (1H, t, J 7.2, Ar), 7.13 (1H, 
dd, J 2.0 and 8.7, Ar), 7.15 (2H, app.d, Ar), 7.18-7.21 (2H, m, Ar), 7.28-7.31 (2H, m, Ar), 7.61-7.62 (1H, app dd, Ar), 
7.66-7.71 (3H,m, Ar); 13C NMR (125 MHz, CDCl3) 14.4, 24.9, 28.6, 35.1, 44.2, 47.4, 53.6, 61.2, 112.3, 120.0, 120.9, 
122.9, 124.5, 124.7, 127.5, 127.5, 128.5, 129.1, 131.1, 132.2, 136.1, 138.9, 144.2, 154.3, 154.7, 166.3; MS (ESI+) m/z 
= 517.3 [M+H]+. 
(S)-Ethyl 4-(3-(5-chloro-2-benzyl-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxamido)benzoate 8{1,8}. 
General procedure C: 15{1} (1 mL, 49.3 µmol) and ethyl 4-isothiocyanatobenzoate (14.1 mg, 75.6 µmol). 8{1,8} (18 
mg, 71%) as a white solid; HPLC purity (as area %) > 97;1H NMR (500 MHz, CDCl3) 1.38 (3H, t, J 7.2, COOCH2CH3), 1.51 
(1H, qt, J 4.0 and 13.3), 1.68 (1H, app.d), 1.88 (1H, app.d), 2.23 (1H, qd, J 4.0 and 12.9), 2.82 (1H, td, J 2.4 and 13.3), 
3.40 (1H, app.t), 3.71 (1H, dd, J 4.1 and 12.6), 4.17 (1H, app.d), 4.27-4.31 (3H, m), 4.35 (2H, q, J 7.2, COOCH2CH3), 
6.42 (1H, s, NH), 7.10 (1H, t, J 7.3, Ar), 7.18-7.25 (5H, m, Ar), 7.34 (1H, d, J 8.7, Ar), 7.36 (2H, d, J 8.8, Ar), 7.75 (1H, d, J 
2.0, Ar), 7.97 (2H, d, J 8.8, Ar); 13C NMR (125 MHz, CDCl3) 14.4, 24.9, 28.6, 35.1, 44.2, 47.2, 53.5, 60.8, 112.2, 118.7, 
119.9, 122.8, 125.0, 127.4, 127.8, 128.4, 129.0, 130.7, 132.2, 136.0, 143.0, 144.1, 154.1, 154.3, 166.2; MS (ESI+) m/z 
= 517.3 [M+H]+; HRMS C29H3035ClN4O3 [M+H]+ calcd 517.2001, obsd 517.2004. 
(S)-3-(5-Chloro-2-benzyl-1H-benzo[d]imidazol-1-yl)-N-(4-fluorophenyl)piperidine-1-carboxamide 8{1,9}. 
General procedure C: 15{1} (26 mg, 80 µmol) and 4-fluorophenyl isocyanate (14 µl, 120 µmol). 8{1,9} (22 mg, 60%), 
white solid; HPLC purity (as area %) > 90; 1H NMR (500 MHz, CDCl3) 1.43 (1H, qt, J 4.0 and 13.2), 1.60 (1H, app.d), 
1.78 (1H, app. d), 2.15 (1H, qd, J 4.1 and 12.9), 2.73 (1H, td, J 2.4 and 13.1), 3.30 (1H, t, J 12.2), 3.61 (1H, m), 4.07 (1H, 
app.d), 4.19-4.24 (1H, m), 4.25 (2H,s), 6.03 (1H, s, NH), 6.91 (2H, app.t, Ar), 7.04 (1H, t, J 7.3, Ar), 7.11-7.19 (6H, m, 
Ar), 7.29 (1H, d, J 8.7, Ar), 7.68 (1H, d, J 2.0, Ar); 13C NMR (125 MHz, CDCl3) 24.9, 28.6, 35.2, 44.2, 47.3, 53.5, 112.2, 
115.5 (d, J 22.6 Hz), 119.9, 122.4 (d, J 7.5 Hz), 122.8, 127.3, 127.8, 128.4, 129.0, 132.2, 134.4, 136.1, 144.2, 154.3, 
155.0, 159.2 (d, J 242.8 Hz); 19F NMR (376.2 MHz, CDCl3) -119.3; MS (ESI+) m/z = 463.3 [M+H]+; HRMS C29H2535ClFN4O 
[M+H]+ calcd 463.1695, obsd 463.1695. 
 (S)-3-(5-Chloro-2-benzyl-1H-benzo[d]imidazol-1-yl)-N-cyclohexylpiperidine-1-carboxamide 8{1,10}. 
 General procedure C: 15{1} (1 mL, 49 µmol) and cyclohexyl isocyanate (11 µl, 76 µmol). 8{1,10} (19 mg, 85%), white 
solid; HPLC purity (as area %) > 97; 1H NMR (500 MHz, CDCl3) 1.00-1.08 (2H, m), 1.07 (1H, qt, J 3.6 and 12.5), 1.31-
1.45 (3H, m), 1.55 (1H, app.d), 1.63 (1H, app.d), 1.69-1.72 (2H, m), 1.75-1.79 (1H, m), 1.88-1.95 (2H, m), 2.14 (1H, qd, 
J 12.8 and 4.1), 2.72 (1H, td, J 13.1 and 2.6), 3.28 (1H, app.t), 3.56-3.63 (1H, m), 3.67 (1H, dd, J 12.6 and 4.6), 3.92 
(1H, dd, J 13.4 and 1.5), 4.02 (1H, d, J 7.5), 4.25 (1H, dt, J 12.0 and 4.4), 4.32 (1H, d, J 15.9), 4.38 (1H, d, J 15.9), 7.17 
(1H, dd, J 8.7 and 2.0, Ar), 7.21-7.32 (5H, m, Ar), 7.35 (1H, d, J 8.7, Ar), 7.75 (1H, d, J 2.0, Ar); 13C NMR (125 MHz, 
CDCl3) 24.7, 25.1, 25.6, 28.6, 33.9, 33.9, 35.2, 44.2, 47.1, 49.6, 53.5, 112.3, 119.9, 122.5, 127.3, 127.6, 128.4, 128.9, 
132.3, 136.3, 144.2, 154.4, 156.9; MS (ESI+) m/z = 451.4 [M+H]+.  
 (S)-3-(5-Chloro-2-(3-chlorobenzyl)-1H-benzo[d]imidazol-1-yl)-N-(4-nitrophenyl)piperidine-1-carboxamide 8{2,1}. 
General procedure C: 15{2} (1 mL, 49.3 µmol) and 4-nitrophenyl isocyanate (12.4 mg, 75.6 µmol). 8{2,1} (2 mg, 8%), 
yellow solid; HPLC purity (as area %) > 97; 1H NMR (500 MHz, CDCl3) 1.49 (1H, qt, J 4.0 and 13.2), 1.66 (1H, app.d), 
1.87 (1H, app.d), 2.22 (1H, qd, J 4.1 and 12.9), 2.88 (1H, td, J 2.3 and 13.3), 3.39 (1H, app.t), 3.88 (1H, app.d), 4.08 
(1H, app.d), 4.17-4.25 (2H, m), 4.27 (1H, d, J 16.4), 6.73 (1H, br.s, NH), 7.02 (2H, app.t, Ar), 7.10-7.13 (2H, m, Ar), 7.16 
(1H, dd, J 1.9 and 8.7, Ar), 7.32 (1H, d, J 8.7, Ar), 7.43 (2H, d, J 9.2, Ar), 7.67 (1H, d, J 1.9, Ar), 8.11 (2H, d, J 9.2, Ar); 13C 
NMR (125 MHz, CDCl3) 25.0, 28.6, 34.6, 44.6, 47.1, 53.4, 112.2, 118.7, 119.9, 123.1, 125.0, 126.5, 127.6, 128.1, 128.4, 
130.3, 132.0, 134.9, 137.8, 142.8, 143.8, 144.9, 153.4, 153.6; MS (ESI+) m/z = 524.2 [M+H]+. 
 (S)-3-(5-Chloro-2-(3-chlorobenzyl)-1H-benzo[d]imidazol-1-yl)-N-(4-acetylphenyl)piperidine-1-carboxamide 8{2,2}. 
General procedure C: 15{2} (1 mL, 49.3 µmol) and 4-acetylphenyl isocyanate (11.9 mg, 75.6 µmol). 8{2,2} (24 mg, 
93%), white solid; HPLC purity (as area %) > 95; 1H NMR (400MHz, CDCl3) 1.51 (1H, qt, J 3.7 and 12.8), 1.65 (1H, 
app.dd), 1.87 (1H, app.d), 2.23 (1H, qd, J 4.1 and 12.8), 2.53 (3H, s, COCH3), 2.88 (1H, td, J 2.3 and 13.7), 3.39 (1H, t, J 
11.9), 3.94 (1H, app. dd), 4.12 (1H, app.d), 4.20-4.32 (3H, m), 6.80 (1H, s, NH), 7.03-7.08 (2H, m, Ar), 7.13 (1H, d, J 
7.8, Ar), 7.16-7.20 (2H, m, Ar), 7.35 (1H, d, J 8.7, Ar), 7.40 (2H, d, J 8.7, Ar), 7.71 (1H, d, J 1.8, Ar), 7.87 (2H, d, J 8.7); 
13C NMR (100MHz, CDCl3) 25.0, 26.5, 28.8, 34.7, 44.7, 47.2, 53.6, 118.8, 120.0,123.1, 126.6, 127.7, 127.9, 128.5, 
129.8, 130.3, 132.1, 134.9, 137.9, 143.5, 153.5, 154.3, 197.1; MS (ESI+) m/z = 521.3 [M+H]+. 
(S)-3-(5-Chloro-2-(3-chlorobenzyl)-1H-benzo[d]imidazol-1-yl)-N-(3,4,5-trimethoxyphenyl)piperidine-1-carboxamide 
8{2,3}. 
General procedure C: 15{2} (1 mL, 49.3 µmol) and 3,4,5-(trimethoxy)phenyl isocyanate (16 mg, 76 µmol). 8{2,3} (27 
mg, 97%), white solid; HPLC purity (as area %) > 97; 1H NMR (500 MHz, CDCl3) 1.47 (1H, qt, J 4.0 and 13.2), 1.60 (1H, 
app.dd), 1.82 (1H, app.d), 2.18 (1H, qd, J 4.0 and 12.8), 2.81 (1H, td, J 2.4 and 13.2), 3.34 (1H, app.t), 3.73 (3H, s, 
OCH3), 3.76 (6H, s, OCH3), 3.82 (1H, app. dd), 4.03 (1H, app.d), 4.16-4.23 (2H, m), 4.27 (1H, d, J 16.0), 6.21 (1H, s, NH), 
6.54 (2H, s, Ar), 7.02 (1H, d, J 7.8, Ar), 7.04-7.06 (1H, m, Ar), 7.10 (1H, d, J 7.8, Ar), 7.12-7.14 (2H, m, Ar), 7.31 (1H, d, J 
8.7, Ar), 7.68 (1H, d, J 2.0, Ar); 13C NMR (125 MHz, CDCl3) 25.0, 28.8, 34.7, 44.6, 47.2, 53.6, 56.1, 61.0, 98.1, 112.3, 
120.0, 122.9, 126.6, 127.6, 127.9, 128.5, 130.2, 132.2, 134.3, 134.7, 134.8, 138.0, 144.1, 153.3, 153.5, 154.9; MS 
(ESI+) m/z = 569.3 [M+H]+. 
 (S)-3-(5-Chloro-2-(3-chlorobenzyl)-1H-benzo[d]imidazol-1-yl)-N-(4-trifluoromethoxy)phenylpiperidine-1-
carboxamide 8{2,4}. 
General procedure C: 15{2} (1 mL, 49 µmol) and 4-(trifluoromethoxy)phenyl isocyanate (11 µl, 76 µmol). 8{2,4} (26 
mg, 94%), white solid; HPLC purity (as area %) > 96; 1H NMR (500 MHz, CDCl3) 1.53 (1H, qt, J 4.0 and 13.2), 1.69 (1H, 
app.d), 1.89 (1H, app.d), 2.22-2.29 (1H, m), 2.89 (1H, td, J 2.5 and 13.2), 3.40 (1H, app.t), 3.90-3.93 (1H, m), 4.09 (1H, 
app.d), 4.21-4.28 (1H, m), 4.25 (1H, d, J 16.1), 4.32 (1H, d, J 16.1), 6.44 (1H, br.s, NH), 7.06 (1H, app.d, Ar), 7.10 (1H, 
app.d, Ar), 7.14-7.19 (4H, m, Ar), 7.21 (1H, dd, J 2.0 and 8.7, Ar), 7.32 (2H, d, J 9.1, Ar), 7.37 (1H, d, J 8.7, Ar), 7.74 
(1H, d, J 2.0, Ar); 13C NMR (125 MHz, CDCl3) 25.0, 28.7, 34.6, 44.6, 47.2, 53.5, 112.2, 120.5 (q, J 256.8), 120.0, 121.2, 
121.7, 123.0, 126.5, 127.6, 127.9, 128.4, 130.2, 132.2, 134.8, 137.3, 137.9, 144.1, 144.8, 153.4, 154.7; 19F NMR (470.7 
MHz, CDCl3) -58.14; MS (ESI+) m/z = 563.2 [M+H]+. 
(S)-3-(5-Chloro-2-(3-chlorobenzyl)-1H-benzo[d]imidazol-1-yl)-N-(4-trifluoromethylphenyl)piperidine-1-
carboxamide 8{2,5}. 
General procedure C: 15{2} (1 mL, 49 µmol) and 4-(trifluoromethyl)phenyl isocyanate (11 µl, 78 µmol). 8{2,5} (23 
mg, 85%), white solid; HPLC purity (as area %) > 96; 1H NMR (400MHz, CDCl3) 1.53 (1H, qt, J 4.1 and 13.3), 1.68 (1H, 
app.d), 1.89 (1H, app.d), 2.25 (1H, qd, J 4.1 and 12.7), 2.90 (1H, td, J 2.3 and 13.3), 3.42 (1H, app.t), 3.94 (1H, app.d), 
4.10 (1H, app.d), 4.23-4.31 (2H, m), 4.34 (1H, d, J 15.6), 6.49 (1H, s, NH), 7.06-7.09 (2H, m, Ar), 7.16 (1H, app.t, Ar), 
7.18-7.21 (2H, m, Ar), 7.31 (1H, d, J 8.7, Ar), 7.42 (2H, d, J 8.7, Ar), 7.53 (2H, d, J 8.7, Ar), 7.71 (1H, s, Ar); 13C NMR 
(75MHz, CDCl3) 25.1, 28.9, 34.8, 45.0, 47.6, 53.7, 112.2, 119.5, 120.2, 125.4, 126.5 (q, J 3.8), 126.6, 127.7, 128.3, 
128.6, 130.3, 132.3, 135.1, 138.2, 142.0, 153.5, 154.4; 19F NMR (376.2 MHz, CDCl3) -61.9; MS (ESI+) m/z = 547.3.  
 (S)-3-(5-Chloro-2-(3-chlorobenzyl)-1H-benzo[d]imidazol-1-yl)-N-phenylpiperidine-1-carboxamide 8{2,6}.  
General procedure C: 15{2} (1 mL, 49 µmol) and phenyl isocyanate (8 µl, 76 µmol). 8{2,6} (23 mg, 98%), white solid; 
HPLC purity (as area %) > 98; 1H NMR (500 MHz, CDCl3) 1.43 (1H, qt, J 4.0 and 13.2), 1.56 (1H, app.dd), 1.78 (1H, 
app.d), 2.16 (1H, qd, J 4.0 and 12.8), 2.79 (1H, td, J 2.5 and 13.2), 3.30 (1H, app.t), 3.87 (1H, app. dd), 4.01 (1H, 
app.d), 4.15-4.20 (2H, m), 4.25 (1H, d, J 16.1), 6.37 (1H, s, NH), 6.98-7.04 (3H, m, Ar), 7.07-7.12 (2H, m, Ar), 7.13 (1H, 
dd, J 2.0 and 7.8, Ar), 7.22-7.23 (4H, m, Ar), 7.30 (1H, d, J 8.7, Ar), 7.67 (1H, d, J 2.0, Ar); 13C NMR (125 MHz, CDCl3) 
25.0, 28.8, 34.6, 44.7, 47.3, 53.5, 112.3, 120.0, 120.3, 122.9, 123.6, 126.5, 127.6, 127.9, 128.5, 129.0, 130.2, 132.2, 
134.9, 138.0, 138.6, 144.1, 153.6, 155.1; MS (ESI+) m/z = 479.3 [M+H]+. 
(S)-Ethyl 3-(3-(5-chloro-2-(3-chlorobenzyl)-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxamido)benzoate 8{2,7}. 
General procedure C: 15{2} (1 mL, 49 µmol) and 3-isothiocyanatobenzoate (12 µl, 76 µmol). 8{2,7} (22 mg, 81%), 
white solid; HPLC purity (as area %) > 98; 1H NMR (500 MHz, CDCl3) 1.37 (3H, t, J 7.1, CH2CH3), 1.53 (1H, qt, J 4.0 and 
13.3), 1.66 (1H, app.d), 1.87 (1H, app.d), 2.25 (1H, qd, J 4.1 and 12.8), 2.88 (1H, td, J 2.4 and 13.3), 3.41 (1H, app.t), 
3.95 (1H, app.d), 4.13 (1H, app.d), 4.24-4.30 (1H, m), 4.28 (1H, d, J 16.1), 4.34 (1H, d, J 16.1), 4.34 (2H, d, J 7.1, 
CH2CH3), 6.60 (1H, s, NH), 7.07-7.11 (2H, m, Ar), 7.15-7.19 (2H, m, Ar), 7.20 (1H, d, J 8.7, Ar), 7.34-7.39 (2H, m, Ar), 
7.68 (1H, ddd, J 1.0, 2.3 and 8.7, Ar), 7.71-7.74 (2H, m, Ar), 7.80 (1H, app.t, Ar); 13C NMR (125 MHz, CDCl3) 14.3, 24.9, 
28.7, 34.6, 44.6, 47.2, 53.5, 61.1, 112.3, 119.9, 120.9, 123.0, 124.5, 124.6, 126.5, 127.6, 127.9, 128.4, 129.0, 130.2, 
131.1, 132.1, 134.8, 137.9, 138.9, 153.5, 154.8, 166.3; MS (ESI+) m/z = 551.3 [M+H]+. 
(S)-Ethyl 4-(3-(5-chloro-2-(3-chlorobenzyl)-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxamido)benzoate 8{2,8}. 
General procedure C: 15{2} (1 mL, 49 µmol) and 4-isocyanatobenzoate (14 mg, 76 µmol). 8{2,8} (26 mg, 96%), white 
solid; HPLC purity (as area %) > 96; 1H NMR (400MHz, CDCl3) 1.35 (3H, t, J 7.3, CH2CH3), 1.49 (1H, qt, J 4.1 and 13.3), 
1.65 (1H, app.d), 1.85 (1H, app.d), 2.21 (1H, qd, J 4.1 and 12.8), 2.84 (1H, td, J 2.3 and 13.3), 3.37 (1H, app.t), 3.91 
(1H, app. dd), 4.11 (1H, app.d), 4.19 (1H, d, J 16.0), 4.27 (1H, d, J 16.0), 4.31 (2H, q, J 7.3, CH2CH3), 6.80 (1H, s, NH), 
7.02-7.07 (2H, m, Ar), 7.10-7.14 (2H, m, Ar), 7.17 (1H, d, J 1.8 and 8.7, Ar), 7.34 (1H, d, J 8.7, Ar), 7.37 (2H, d, J 8.7, 
Ar), 7.71 (1H, d, J 1.8, Ar), 7.93 (2H, d, J 8.7, Ar); 13C NMR (100MHz, CDCl3) 14.3, 24.9, 28.7, 34.5, 44.6, 47.1, 53.5, 
60.8, 112.2, 118.7, 119.9, 123.0, 124.9, 126.5, 127.6, 127.9, 128.4, 130.2, 130.6, 132.1, 134.8, 137.8, 143.1, 143.9, 
153.4, 154.3, 166.3; MS (ESI+) m/z = 551.3 [M+H]+. 
(S)-3-(5-Chloro-2-(3-chlorobenzyl)-1H-benzo[d]imidazol-1-yl)-N-(4-fluorophenyl)piperidine-1-carboxamide 8{2,9}.  
General procedure C: 15{2} (1 mL, 49 µmol) and 4-fluorophenyl isocyanate (8 µl, 76 µmol). 8{2,9} (16 mg, 65%), 
white solid; HPLC purity (as area %) > 97; 1H NMR (500 MHz, CDCl3) 1.52 (1H, qt, J 4.1 and 13.2), 1.67 (1H, app.d), 
1.87 (1H, app.d), 2.25 (1H, qd, J 4.3 and 12.7), 2.87 (1H, td, J 2.6 and 13.3), 3.39 (1H, app.t), 3.88-3.92 (1H, m), 4.08 
(1H, app.d), 4.22-4.26 (1H, m), 4.26 (1H,d, J 16.0), 4.32 (1H,d, J 16.0), 6.32 (1H, br.s, NH), 6.99 (2H, app.t, Ar), 7.07 
(1H, app.d, Ar), 7.10-7.12 (1H, m, Ar), 7.15-7.25 (5H, m, Ar), 7.38 (1H, d, J 8.7, Ar), 7.74 (1H, d, J 2.0, Ar); 13C NMR 
(125 MHz, CDCl3) 25.0, 28.7, 34.5, 44.6, 47.2, 53.5, 112.3, 115.5 (d, J 22.5), 120.0, 122.3 (d, J 7.9), 122.9, 126.5, 127.6, 
127.9, 128.4, 130.2, 132.2, 134.4 (d, J 2.8), 134.8, 138.0, 144.1, 153.4, 155.0, 159.2 (d, J 242.8); 19F NMR (470.7 MHz, 
CDCl3) -119.23; MS (ESI+) m/z = 497.2.  
(S)-3-(5-Chloro-2-(3-chlorobenzyl)-1H-benzo[d]imidazol-1-yl)-N-cyclohexylpiperidine-1-carboxamide 8{2,10}.  
General procedure C: 15{2} (1 mL, 49 µmol) and cyclohexyl isocyanate (9 µl, 76 µmol). 8{2,10} (25 mg, 99%), white 
solid; HPLC purity (as area %) > 96; 1H NMR (500 MHz, CDCl3) 0.95-1.04 (2H, m), 1.07 (1H, qt, J 12.5 and 3.5), 1.25-
1.34 (2H, m), 1.36 (1H, qt, J 13.1 and 4.0), 1.47 (1H, app.d), 1.54-1.58 (1H, m), 1.62-1.66 (2H, m), 1.71-1.73 (1H, m), 
1.87 (2H, dd, J 12.4 and 2.5), 2.10 (1H, qd, J 12.8 and 4.1), 2.73 (1H, td, J 13.2 and 2.5), 3.22 (1H, t, J 12.1), 3.52-3.60 
(1H, m), 3.78 (1H, app.d), 3.85 (1H, dd, J 12.6 and 4.3), 4.14 (1H, tt, J 12.0 and 4.3), 4.18 (1H, app.d), 4.21 (1H, d, J 
16.0), 4.32 (1H, d, J 16.0), 7.02-7.05 (1H, m, Ar), 7.11 (1H, dd, J 8.7 and 2.0, Ar), 7.14-7.18 (3H, m, Ar), 7.31 (1H, d, J 
8.7, Ar), 7.67 (1H, d, J 2.0, Ar); 13C NMR (125 MHz, CDCl3) 24.8, 25.0, 25.6, 28.7, 33.9, 33.9, 34.6, 44.6, 47.1, 49.6, 
53.4, 112.3, 119.8, 122.8, 126.5, 127.5, 127.7, 128.5, 130.1, 132.2, 134.7, 138.1, 144.0, 153.5, 156.9; MS (ESI+) m/z = 
485.3 [M+H]+. 
(S)-3-(5-Chloro-2-(3-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)-N-(4-nitrophenyl)piperidine-1-carboxamide 8{3,1}. 
General procedure C: 15{3} (1 mL, 49.3 µmol) and 4-nitrophenyl isocyanate (12 mg, 76 µmol). 8{3,1} (19 mg, 74%), 
white solid; HPLC purity (as area %) > 95; 1H NMR (500 MHz ,CDCl3) 1.48 (1H, qt, J 3.9 and 13.2), 1.68 (1H, app.dd), 
1.86 (1H, app.d), 2.17 (1H, qd, J 4.0 and 12.8), 2.79 (1H, td, J 2.4 and 13.2), 3.37 (1H, t, app.t), 3.59 (3H, s, OCH3), 3.72 
(1H, app. dd), 4.17 (2H, br.s, CH2), 4.25 (1H, tt, J 4.4 and 12.0), 6.58 (1H, dd, J 2.1 and 8.2, Ar), 6.64-6.67 (2H, m, Ar), 
6.83 (1H, br.s, NH), 7.08 (1H, app.t, Ar), 7.12 (1H, dd, J 2.0 and 8.7, Ar), 7.27 (1H, d, J 8.7, Ar), 7.43 (2H, d, J 9.2, Ar), 
7.65 (1H, d, J 2.0, Ar), 8.08 (2H, d, J 9.2, Ar); 13C NMR (125 MHz, CDCl3) 24.9, 28.6, 35.1, 44.2, 47.2, 53.5, 55.3, 60.4, 




General procedure C: 15{3} (1 mL, 49.3 µmol) and 4-acetylphenyl isocyanate (12 mg, 76 µmol). 8{3,2} (21 mg, 82%), 
white solid; HPLC purity (as area %) > 96; 1H NMR (400MHz, CDCl3) 1.50 (1H, qt, J 3.7 and 12.8), 1.68 (1H, 
app.dd),1.86 (1H, app.d); 2.20(1H, qd, J 3.7 and 13.3), 2.53 (3H, s, COCH3), 2.80 (1H, td, J 2.3 and 13.3), 3.38 (1H, t, J 
11.9), 3.61 (3H, s, OCH3), 3.77 (1H, app. dd), 4.19 (1H, app.d), 4.25 (2H, s, CH2), 4.30 (1H, tt, J 4.1 and 11.9), 6.62 (1H, 
dd, J 2.3 and 8.2, Ar), 6.69-6.73 (3H, m, Ar + NH), 7.12(1H, app.t, Ar), 7.16 (1H, dd, J 1.8 and 8.7, Ar), 7.32 (1H, d, J 
8.7, Ar), 7.39 (2H, d, J 8.2, Ar), 7.70 (1H, d, J 1.8, Ar), 7.86 (2H, d, J 8.2); 13C NMR (100MHz, CDCl3) 25.0, 26.5, 28.7, 
35.1, 44.3, 47.3, 53.6, 55.3, 112.3, 112.7, 114.4, 118.9, 119.9, 120.6, 122.9, 127.9, 129.7, 130.0, 132.0, 132.2, 137.5, 
143.5, 143.9, 154.2, 160.1, 197.1.  
(S)-3-(5-Chloro-2-(3-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)-N-(3,4,5-trimethoxyphenyl)piperidine-1-
carboxamide 8{3,3}.  
General procedure C: 15{3} (1 mL, 49.3 µmol) and 3,4,5-trimethoxyphenyl isocyanate (15 mg, 76 µmol). 8{3,3} (24 
mg, 87%), white solid; HPLC purity (as area %) > 98; 1H NMR (500 MHz, CDCl3) 1.46 (1H, qt, J 4.0 and 13.2), 1.65 (1H, 
app.dd), 1.80 (1H, app.d), 2.16 (1H, qd, J 4.0 and 12.8), 2.73 (1H, td, J 2.4 and 13.2), 3.32 (1H, t, app.t), 3.57 (3H, s, 
OCH3), 3.63 (1H, app. dd), 3.73 (3H, s, OCH3), 3.76 (6H, s, OCH3), 4.10 (1H, app.d), 4.21 (1H, d, J 16.2), 4.23-4.28 (2H, 
m), 6.10 (1H, s, NH), 6.53 (2H, s, Ar), 6.59 (1H, dd, J 2.0 and 8.3, Ar), 6.68-6.71 (2H, m, Ar), 7.08 (1H, d, J 7.9, Ar), 7.11 
(1H, dd, J 2.0 and 8.7, Ar), 7.29 (1H, d, J 8.7, Ar), 7.67 (1H, d, J 2.0, Ar); 13C NMR 125 MHz, CDCl3) 24.9, 28.7, 35.2, 
44.2, 47.3, 53.6, 55.2, 56.1, 61.0, 98.3, 112.2, 112.7, 114.2, 119.9, 120.6, 122.7, 127.7, 130.0, 132.2, 134.3, 134.7, 
137.6, 144.1, 153.3, 154.2, 155.0, 160.0.  
(S)-3-(5-Chloro-2-(3-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)-N-(4-trifluoromethoxyphenyl) piperidine-1-
carboxamide 8{3,4}. 
General procedure C: 15{3} (1 mL, 49.3 µmol) and 4-(trifluoromethoxy)phenyl isocyanate (11 mg, 75 µmol). 8{3,4} 
(27 mg, 98%) as a white solid; HPLC purity (as area %) > 98; 1H NMR (500 MHz, CDCl3) 1.49 (1H, qt, J 4.0 and 13.2), 
1.68 (1H, app.dd), 1.84 (1H, app.d), 2.19 (1H, qd, J 4.1 and 12.8), 2.77 (1H, td, J 2.4 and 13.3), 3.36 (1H, app.t), 3.60 
(3H, s, OCH3), 3.75 (1H, app. dd), 4.16 (1H, app.d), 4.19-4.35 (3H, m), 6.53 (1H, br.d), 6.60-6.62 (1H, m, Ar), 6.69-6.70 
(2H, m, Ar), 7.09-7.14 (3H, m, Ar), 7.16 (1H, dd, J 2.0 and 8.7, Ar), 7.29 (2H, d, J 9.1, Ar), 7.32 (1H, d, J 8.7, Ar), 7.69 
(1H, d, J 2.0, Ar); 13C NMR (125 MHz, CDCl3) 24.8; 28.6; 35.0; 44.1; 47.2; 53.2; 55.1; 112.2; 112.5; 114.3; 119.7; 
120.5(q, J 256.6); 120.5; 121.4; 121.6; 122.8; 127.8; 129.9; 132.1; 137.4; 137.4; 143.8; 144.7; 154.1; 154.7; 19F NMR 
(470.7 MHz, CDCl3) -58.1. 
(S)-3-(5-Chloro-2-(3-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)-N-(4-trifluoromethylphenyl)piperidine-1-
carboxamide 8{3,5} 
General procedure C: 15{3} (1 mL, 49.3 µmol) and 4-(trifluoromethyl)phenyl isocyanate (11.2 µl, 78.4 µmol). 8{3,5} 
(23 mg, 85%) as a white solid; HPLC purity (as area %) > 96; 1H NMR (400MHz, CDCl3) 1.53 (1H, qt, J 4.1 and 13.1), 
1.74 (1H, app.d), 1.89 (1H, app.d), 2.24 (1H, qd, J 4.1 and 12.8), 2.82 (1H, td, J 2.3 and 13.1), 3.40 (1H, app.t), 3.61 
(3H, s, OCH3), 3.71 (1H, app.d), 4.17 (1H, app.d), 4.26 (1H, d, J 16.0), 4.29 (1H, d, J 16.0), 4.28-4.35 (1H, m), 6.33 (1H, 
s, NH), 6.62 (1H, dd, J 2.3 and 8.7, Ar), 6.73-6.75 (2H, m, Ar), 7.14 (1H, app.t, Ar), 7.18 (1H, dd, J 1.8 and 8.7), 7.35 
(1H, d, J 8.7, Ar), 7.39 (2H, d, J 8.7, Ar), 7.52 (2H, d, J 8.7, Ar), 7.72 (1H, d, J 1.8, Ar); 13C NMR (75MHz, CDCl3) 25.0, 
28.8, 35.3, 44.6, 47.6, 53.7, 55.3, 112.1, 112.9, 114.5, 119.5, 120.2, 120.7, 122.9, 126.1 (q, J 3.8), 128.1, 130.0, 132.4, 
132.4, 137.8, 142.1, 144.4, 154.2, 154.3, 160.4; 19F NMR (376.2 MHz, CDCl3) -61.9. 
 (S)-3-(5-Chloro-2-(3-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)-N-phenylpiperidine-1-carboxamide 8{3,6} 
General procedure C: 15{3} (1 mL, 49.3 µmol) and phenyl isocyanate (8.1 µl, 75.6 µmol). 8{3,6} (23 mg, 98%) as a 
white solid; HPLC purity (as area %) > 97; 1H NMR (500 MHz, CDCl3) 1.55 (1H, qt, J 4.0 and 13.2), 1.74 (1H, app.dd), 
1.89 (1H, m), 2.27 (1H, qd, J 4.0 and 12.8), 2.84 (1H, td, J 2.6 and 13.2), 3.41 (1H, t, app.t), 3.65 (3H, s, OCH3), 3.76 
(1H, dd, J 4.4 and 12.7), 4.18 (1H, br.d), 4.32 (1H, d, J 16.0), 4.34-4.39( 2H, m), 6.16 (1H, br.s, NH), 6.67 (1H, dd, J 2.0 
and 8.2, Ar), 6.78-6.80 (2H, m, Ar), 7.09 (1H, tt, J 2.1 and 6.5, Ar), 7.19 (1H, app.t, Ar), 7.12( 1H, dd, J 2.0 and 8.6, Ar), 
7.29 (4H, m, Ar), 7.39 (1H, d, J 8.6, Ar), 7.78 (1H, d, J 2.0, Ar); 13C NMR (125 MHz, CDCl3) 24.9, 28.7, 35.2, 44.3, 47.3, 
53.5, 55.2, 112.2, 112.6, 114.3, 119.9, 120.3, 120.6, 122.7, 123.5, 127.7, 128.9, 129.9, 132.2, 137.6, 138.6, 144.2, 
154.2, 154.9, 160.0. 
(S)-Ethyl 3-(3-(5-chloro-2-(3-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxamido)benzoate 8{3,7}. 
General procedure C: 15{3} (1 mL, 49.3 µmol) and ethyl 3-isothiocyanatobenzoate (12 µl, 76 µmol). 8{3,7} (26 mg, 
96%) as a white solid; HPLC purity (as area %) > 98; 1H NMR (300MHz, CDCl3) 1.38 (1H, t, J 7.2, CH2CH3), 1.54 (1H, qt, J 
3.6 and 13.1), 1.72 (1H, app.dd), 1.87 (1H, app.d), 2.20 (1H, qd, J 4.0 and 12.7), 2.80 (1H, td, J 2.2 and 13.1), 3.38(1H, 
app.t), 3.63 (3H, s, OCH3), 3.77 (1H, app. dd), 4.21 (1H, app.d), 4.30 (2H, s, CH2), 4.36 (2H, q, J 7.2), 6.54 (1H, br.d), 
6.65-6.69 (1H, m, Ar), 6.77 (2H, d, J 8.3, Ar), 7.17 (1H, app.t, Ar), 7.20 (1H, m, Ar), 7.32-7.39 (2H, m, Ar), 7.67-7.81 
(4H, m, Ar); 13C NMR (100MHz, CDCl3) 14.3, 24.8, 28.6, 35.0, 44.1, 47.2, 53.5, 55.2, 61.1, 112.2, 112.5, 114.3, 119.8, 
120.5, 121.0, 122.7, 124.4, 124.7, 127.7, 128.9, 129.9, 131.0, 132.1, 137.5, 138.9, 144.0, 154.2, 154.7, 160.0, 166.3. 
(S)-Ethyl 4-(3-(5-chloro-2-(3-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxamido)benzoate 5{3,8}. 
General procedure C: 15{3} (1 mL, 49.3 µmol) and ethyl 4-isothiocyanatobenzoate (14.1 mg, 75.6 µmol). 8{3,8} (23 
mg, 85%), white solid; HPLC purity (as area %) > 97; 1H NMR (400MHz, CDCl3) 1.34 (3H, t, J 7.6, CH2CH3), 1.45-1.55 
(1H, m), 1.69 (1H, app.d), 1.85 (1H, app.d), 2.14-2.25 (1H, m), 2.79 (1H, app.t), 3.37 (1H, app.t), 3.60 (3H, s, OCH3), 
3.71-3.75 (1H, m), 4.17 (1H, app.d), 4.24-4.34 (5H, m), 6.58 (1H, s, NH), 6.58 (1H, dd, J 2.3 and 8.2, Ar), 6.72 (2H, 
app.d, Ar), 7.11 (1H, app.t, Ar), 7.16 (1H, dd, J 2.4 and 8.7, Ar), 7.32 (1H, d, J 8.7, Ar), 7.36 (1H, d, J 8.7, Ar), 7.70 (1H, 
app.t, Ar), 7.93 (2H, dd, J 1.4 and 8.7, Ar); 13C NMR (100MHz, CDCl3) 14.3, 24.9, 28.6, 35.1, 44.2, 47.2, 53.5, 55.2, 




General procedure C: 15{3} (1 mL, 49.3 µmol) and 4-fluorophenyl isocyanate (8.4 µl, 75.6 µmol). 8{3,9} (23 mg, 96%), 
white solid; HPLC purity (as area %) > 97; 1H NMR (400 MHz, CDCl3) 1.50 (1H, qt, J 4.1 and 13.3), 1.69 (1H, app.d), 
1.83 (1H, app.d), 2.20 (1H, qd, J 4.1 and 12.6), 2.76 (1H, td, J 2.3 and 13.3), 3.35 (1H, app.t), 3.61 (3H, s, OCH3), 3.67-
3.72 (1H, m), 4.17 (1H, app.d), 4.12-4.16 (1H, app.d), 4.21-4.32 (2H, m), 6.26 (1H, s, NH), 6.61 (1H, dd, J 2.3 and 8.7, 
Ar), 6.71-6.73 (2H, app.d, Ar), 6.95 (2H, app.t, Ar), 7.10-7.21 (4H, m, Ar), 7.33 (1H, d, J 8.7, Ar), 7.71 (1H, d, J 8.7, Ar); 
13C NMR (100 MHz, CDCl3) 24.9, 28.6, 35.0, 44.1, 47.3, 53.5, 55.2, 112.2, 112.4, 114.3, 115.4 (d, J 22.0 Hz), 119.8, 
120.5, 122.5 (d, J 7.7 Hz), 122.7, 127.7, 129.9, 132.2, 134.5, 134.5(d, J 2.9), 137.5, 144.0, 154.1, 155.0, 159.1 (d, J 
243.5 Hz), 160.0; 19F NMR (376.2 MHz, CDCl3) -119.2. 
(S)-3-(5-Chloro-2-(3-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)-N-cyclohexylpiperidine-1-carboxamide 8{3,10}. 
General procedure C: 15{3} (1 mL, 49 µmol) and cyclohexyl isocyanate (9.4 µl, 76 µmol). 8{3,10} (24 mg, 99%), white 
solid; HPLC purity (as area %) > 93; 1H NMR (500 MHz, CDCl3) 0.94-1.02 (2H, m), 1.06 (1H, qt, J 12.5 and 3.5), 1.23-
1.40 (3H, m), 1.50 (1H, app.d), 1.55 (1H, dt, J 12.9 and 3.5), 1.62-1.65 (2H, m), 1.71 (1H, app dt), 1.81-1.88 (2H, m), 
2.07 (1H, qd, J 12.8 and 4.1), 2.67 (1H, td, J 13.2 and 2.6), 3.22 (1H, t, J 12.1), 3.53 (1H, dtt, J 14.7, 10.9 and 3.9), 3.67 
(3H, s, OCH3), 3.70 (1H, dd, J 12.5 and 4.3), 3.85 (1H, app.d), 4.09 (1H, app.d), 4.18-4.21 (1H, m), 4.21 (1H, d, J 15.8), 
4.30 (1H, d, J 15.8), 6.70-6.71 (3H, m, Ar), 7.10 (1H, dd, J 8.7 and 2.0, Ar), 7.14 (1H, app.t, Ar), 7.29 (1H, d, J 8.7, Ar), 
7.67 (1H, d, J 2.0, Ar); 13C NMR (125 MHz, CDCl3) 24.7, 25.0, 25.1, 25.6, 28.6, 33.8, 33.9, 35.0, 44.2, 47.1, 49.6, 53.4, 
55.2, 112.3, 112.9, 113.9, 119.8, 120.6, 122.6, 127.6, 129.9, 132.2, 137.6, 144.0, 154.2, 156.9, 160.0. 
(S)-3-(5-Chloro-2-(4-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)-N-(4-acetylphenyl)piperidine-1-carboxamide 
8{4,2}. 
General procedure C: 15{4} (1 mL, 49 µmol) and 4-acetylphenyl isocyanate (12 mg, 76 µmol). 8{4,2} (13 mg, 51%) as 
a white solid; HPLC purity (as area %) > 98; 1H NMR (400MHz, CDCl3) 1.51 (1H, qt, J 4.1 and 13.3), 1.67 (1H, app.d), 
1.87 (1H, app.d), 2.20 (1H, qd, J 4.1 and 12.8), 2.53 (3H, s, COCH3), 2.82 (1H, td, J 2.3 and 13.3), 3.39 (1H, app.t), 3.59 
(3H, s, OCH3), 3.79 (1H, dd, J 4.1 and 12.4), 4.18 (1H, d, J 16.0), 4.23 (1H, d, J 16.0), 4.30 (1H, tt, J 4.6 and 11.9), 6.69 
(1H, s, NH), 6.75 (2H, d, J 8.7, Ar), 7.16 (1H, dd, J 2.3 and 8.7, Ar), 7.32 (2H, d, J 8.7, Ar), 7.39 (1H, d, J 8.7, Ar), 7.70 
(1H, d, J 2.3, Ar), 7.85 (1H, d, J 8.7, Ar); 13C NMR (100MHz, CDCl3) 24.9, 26.4, 28.6, 34.2, 44.2, 47.2, 53.5, 55.1, 112.1, 
114.3, 118.7, 119.8, 122.7, 127.7, 127.8, 129.4, 129.6, 131.2, 143.4, 143.9, 154.2, 154.6, 158.7, 197.0. 
(S)-3-(5-Chloro-2-(4-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)-N-(3,4,5-trimethoxyphenyl)piperidine-1-
carboxamide 8{4,3}. 
General procedure C: 15{4} (1 mL, 49 µmol) and 3,4,5-(trimethoxy)phenyl isocyanate (16 mg, 76 µmol). 8{4,3} (26 
mg, 93%), white solid; HPLC purity (as area %) > 95; 1H NMR (400MHz, CDCl3) 1.53 (1H, qt, J 4.1 and 13.3), 1.70 (1H, 
app.d), 1.87 (1H, app.d), 2.22 (1H, qd, J 4.1 and 12.8), 2.79 (1H, td, J 2.3 and 13.3), 3.38 (1H, t, J 11.9), 3.54 (3H, s, 
OCH3), 3.68 (1H, m), 3.78 (3H, s, OCH3), 3.81 (6H, s, 2 x OCH3), 4.17 (1H, app.d), 4.24 (1H, d, J 16.5), 4.28 (1H, d, J 
16.5), 4.32 (1H, tt, J 4.1 and 11.9), 6.09 (1H, s, NH), 6.58 (2H, s, Ar), 6.75 (2H, d, J 8.7, Ar), 7.11 (2H, d, J 8.7, Ar), 7.16 
(1H, dd, J 1.8 and 8.7, Ar), 7.35 (2H, d, J 8.7, Ar), 7.71 (1H, d, J 1.8, Ar); 13C NMR (100MHz, CDCl3) 25.0, 28.7, 34.3, 
44.1, 47.4, 53.7, 55.1, 56.1, 61.0, 98.1, 112.3, 114.4, 119.9,122.8, 127.8, 129.5, 132.2, 134.2, 134.6, 144.2, 153.3, 
154.7, 155.0, 158.8. 
(S)-3-(5-Chloro-2-(4-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)-N-(4-trifluoromethoxyphenyl)piperidine-1-
carboxamide 8{4,4}. 
General procedure C: 15{4} (1 mL, 49 µmol) and 4-(trifluoromethoxy)phenyl isocyanate (11 µl, 76 µmol). 8{4,4} (27 
mg, 98%) as a white solid; HPLC purity (as area %) > 96; 1H NMR (500 MHz, CDCl3) 1.54 (1H, qt, J 4.0 and 13.1), 1.74 
(1H, app.d), 1.89 (1H, app.d), 2.20-2.28 (1H, m), 2.83 (1H, td, J 2.2 and 13.2), 3.39 (1H, app.t), 3.57 (3H, s, OCH3), 3.67 
(1H, dd, J 4.0 and 12.5), 4.20 (1H, app.d), 4.20-4.23 (2H, m), 4.30 (1H, tt, J 4.3 and 12.0), 6.28 (1H, s, NH), 6.76 (2H, d, 
J 8.7, Ar), 7.09 (2H, d, J 8.6, Ar), 7.13 (2H, d, J 8.6, Ar), 7.18 (1H, d, J 1.9 and 8.7, Ar), 7.30 (2H, d, J 8.6, Ar), 7.35 (1H, d, 
J 8.7, Ar), 7.73 (1H, d, J 1.9, Ar); 13C NMR (125 MHz, CDCl3) 24.9, 28.6, 34.2, 44.1, 47.3, 53.5, 55.0, 112.2, 114.3, 119.9, 
120.5 (q, J 256.6), 121.3, 121.6, 127.8 (q, J 5.2), 129.4, 132.2, 137.3, 144.1, 144.8, 154.6, 154.6, 158.7; 19F NMR (470.7 
MHz, CDCl3) -58.2.  
(S)-3-(5-Chloro-2-(4-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)-N-(4-trifluoromethylphenyl)piperidine-1-
carboxamide 8{4,5}. 
General procedure C: 15{4} (1 mL, 49 µmol) and 4-(trifluoromethyl)phenyl isocyanate (11 µl, 78 µmol). 8{4,5} (22 
mg, 82%), white solid; HPLC purity (as area %) > 97; 1H NMR (400MHz, CDCl3) 1.52 (1H, qt, J 4.1 and 13.3), 1.72 (1H, 
app.d), 1.88 (1H, app.d), 2.22 (1H, qd, J 4.1 and 12.8), 2.80 (1H, td, J 2.3 and 13.3), 3.39 (1H, app.t), 3.56 (3H, s, 
OCH3), 3.70 (1H, app.d), 4.18-4.20 (3H, m), 4.30 (1H, tt, J 4.1 and 11.9), 6.48 (1H, s, NH), 6.74 (2H, d, J 8.7, Ar), 7.07 
(2H, d, J 8.7, Ar), 7.16 (1H, dd, J 2.3 and 8.7), 7.33 (1H, d, J 8.7, Ar), 7.39 (2H, d, J 8.7, Ar), 7.50 (2H, d, J 8.7, Ar), 7.71 
(1H, d, J 2.3, Ar); 13C NMR (75MHz, CDCl3) 25.3, 29.1, 34.7, 44.8, 47.9, 53.9, 55.6, 112.4, 114.9, 119.8, 120.4, 123.1, 
126.4 (q, J 3.8), 128.3, 128.4, 129.8, 132.4, 142.3, 144.7, 154.7, 155.0, 159.4; 19F NMR (376.2 MHz, CDCl3) -61.9; MS 
(ESI+) m/z = 543.3. 
 (S)-3-(5-Chloro-2-(4-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)-N-phenylpiperidine-1-carboxamide 8{4,6}. 
General procedure C: 15{4} (1 mL, 49.3 µmol) and phenyl isothocyanate (8.1 µl, 75.6 µmol). 8{4,6} (18 mg, 77%), 
white solid; HPLC purity (as area %) > 99; 1H NMR (400MHz, CDCl3) 1.49 (1H, qt, J 4.1 and 13.3), 1.65,(1H, app.d), 
1.86,(1H, app.d), 2.19,(1H, qd, J 4.1 and 12.8), 2.78 (1H, td, J 2.3 and 13.3), 3.35,(1H, app.t), 3.57,(3H, s, OCH3), 3.75 
(1H, dd, J 4.1 and 12.8), 4.13 (1H, app.d), 4.19 (1H, d, J 16.0), 4.24 (1H, d, J 16.0), 4.29 (1H, tt, J 4.6 and 12.4), 6.28 
(1H, s, NH), 6.75 (2H, d, J 8.7, Ar), 7.10 (1H, m, Ar), 7.08 (1H, d, J 8.7, Ar), 7.15 (1H, dd, J 2.3 and 8.7), 7.25-7.26 (5H, 
m, Ar), 7.33 (1H, d, J 8.7, Ar), 7.70 (1H, d, J 2.3, Ar); 13C NMR (100MHz, CDCl3) 24.8, 28.6, 34.2, 44.2, 47.3, 53.4, 55.0, 
112.2, 114.3, 119.8, 120.3, 122.6, 123.5, 127.6, 127.8, 128.9, 129.4, 132.2, 138.6, 144.0, 154.7, 155.0, 158.7; MS 
(ESI+) m/z = 475.35 [M+H]+. 
(S)-Ethyl 3-(3-(5-chloro-2-(4-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxamido)benzoate 8{4,7}. 
General procedure C: 15{4} (1 mL, 49 µmol) and 3-isocyanatobenzoate (12 µl, 76 µmol). 8{4,7} (23 mg, 85%), white 
solid; HPLC purity (as area %) > 98; 1H NMR (400MHz, CDCl3) 1.33 (3H, t, J 4.1, CH2CH3), 1.48 (1H, qt, J 4.1 and 13.3), 
1.62 (1H, app.d), 1.82 (1H, app.d), 2.17 (1H, qd, J 4.1 and 12.8), 2.78 (1H, td, J 2.3 and 13.3), 3.36 (1H, app.t), 3.55 
(3H, s, OCH3), 3.82 (1H, dd, J 4.1 and 12.8), 4.15 (1H, d, J 16.0), 4.17 (1H, app.d), 4.23 (1H, d, J 16.0), 4.25-4.33 (1H, 
m), 4.30 (2H, q, J 7.3, CH2CH3), 6.70-6.73 (3H, app.d), 7.04 (2H, d, J 8.7, Ar), 7.15 (1H, dd, J 1.8 and 8.7), 7.28-7.33 (2H, 
m, Ar), 7.59-7.62 (1H, m, Ar), 7.63-7.70 (2H, m, Ar), 7.81 (1H, app.d, Ar); 13C NMR (100MHz, CDCl3) 14.3, 24.9, 28.6, 
34.1, 44.2, 47.2, 53.4, 55.0, 61.0, 112.2, 114.2, 119.7, 121.1, 124.4, 124.8, 127.6, 127.7, 128.9, 129.4, 131.0, 132.2, 
139.0, 144.0, 154.7, 154.9, 158.7, 166.3; MS (ESI+) m/z = 547.3 [M+H]+. 
(S)-Ethyl 4-(3-(5-chloro-2-(4-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)piperidine-1-carboxamido)benzoate 8{4,8}. 
General procedure C: 15{4} (1 mL, 49.3 µmol) and 4-isocyanatobenzoate (14.1 mg, 75.6 µmol). 8{4,8} (22 mg, 82%), 
white solid; HPLC purity (as area %) > 97; 1H NMR (400MHz, CDCl3) 1.35 (3H, t, J 7.3, CH2CH3), 1.50 (1H, qt, J 4.1 and 
13.3), 1.67 (1H, app.d), 1.86 (1H, app.d), 2.19 (1H, qd, J 4.1 and 12.8), 2.80 (1H, td, J 2.3 and 13.3), 3.37 (1H, app.t), 
3.59 (3H, s, OCH3), 3.75-3.78 (1H, m), 4.17-4.24 (3H, m), 4.24-4.33 (1H, m), 4.33 (2H, q, J 7.3, CH2CH3), 6.62 (1H, s, 
NH), 6.74 (2H, d, J 8.7, Ar), 6.75 (2H, d, J 8.7, Ar), 7.06 (2H, d, J 8.7, Ar), 7.16 (1H, dd, J 1.8 and 8.7, Ar), 7.31 (2H, d, J 
8.7, Ar), 7.36 (1H, d, J 8.7, Ar), 7.70 (1H, d, J 1.8, Ar), 7.93 (1H, d, J 8.7, Ar); 13C NMR (100MHz, CDCl3) 14.3, 24.9, 28.6, 
34.2, 44.2, 47.2, 53.4, 55.1, 60.7, 112.2, 114.3, 118.6, 119.8, 122.7, 124.9, 127.7, 127.7, 129.4, 130.6, 132.1, 143.0, 
144.0, 154.3, 154.6, 158.7, 166.2; MS (ESI+) m/z = 547.3 [M+H]+. 
(S)-3-(5-Chloro-2-(4-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)-N-(4-fluorophenyl)piperidine-1-carboxamide 
8{4,9}. 
General procedure C: 15{4} (1 mL, 49.3 µmol) and 4-fluorophenyl isocyanate (8.4 µl, 75.6 µmol). 8{4,9} (19 mg, 78%), 
white solid; HPLC purity (as area %) > 97; 1H NMR (400MHz, CDCl3) 1.51 (1H, qt, J 4.1 and 13.3), 1.71 (1H, app.d), 1.86 
(1H, app.d), 2.22 (1H, qd, J 4.1 and 12.8), 2.79 (1H, td, J 2.3 and 13.3), 3.38 (1H, app.t), 3.57 (3H, s, OCH3), 3.70 (1H, 
app.d), 4.15 (1H, app.d), 4.21-4.34 (3H, m), 6.11 (1H, s, NH), 6.76 (2H, d, J 8.7, Ar), 6.96 (2H, app.t, Ar), 7.10 (2H, d, J 
8.7, Ar), 7.16-7.22 (3H, m, Ar), 7.35 (1H, d, J 8.7, Ar), 7.71 (1H, d, J 1.4, Ar); 13C NMR (100 MHz, CDCl3) 24.8, 28.6, 
34.1, 44.1, 47.3, 53.5, 55.0, 112.2, 114.3, 115.4 (d, J 22.0 Hz), 119.7, 122.4 (d, J 7.7 Hz), 122.7, 127.7, 129.4, 132.1, 
134.5 (d, J 2.9), 143.9, 154.6, 155.0, 158.7, 159.1 (d, J 243.5 Hz); 19F NMR (376.2 MHz, CDCl3) -119.3; MS (ESI+) m/z = 
493.3 [M+H]+. 
 (S)-3-(5-Chloro-2-(4-methoxybenzyl)-1H-benzo[d]imidazol-1-yl)-N-cyclohexylpiperidine-1-carboxamide 8{4,10}. 
General procedure C: 15{4} (1 mL, 49.3 µmol) and cyclohexyl isocyanate (9.4 µl, 75.6 µmol). 8{4,10} (23 mg, 97%), 
white solid; HPLC purity (as area %) > 96; 1H NMR (500 MHz, CDCl3) 0.93-1.00 (2H, m), 1.07 (1H, qt, J 12.5 and 3.5), 
1.23-1.33 (2H, m), 1.36 (1H, qt, J 13.2 and 4.0), 1.50 (1H, app.d), 1.55 (1H, dt, J 13.0 and 3.6), 1.62-1.65 (2H, m), 1.72 
(1H, app dt), 1.81-1.87 (2H, m), 2.08 (1H, qd, J 12.8 and 4.1), 2.66 (1H, td, J 13.2 and 2.5), 3.23 (1H, t, J 12.1), 3.48-
3.56 (1H, m), 3.66-3.69 (1H, m), 3.70 (3H, s, OCH3), 3.88 (1H, app.d), 4.03-4.05 (1H, m), 4.17-4.23 (1H, m), 4.18 (1H, d, 
J 15.8), 4.26 (1H, d, J 15.8), 6.75 (2H, d, J 8.6, Ar), 7.05 (1H, d, J 8.6, Ar), 7.10 (1H, dd, J 8.7 and 2.0, Ar), 7.29 (1H, d, J 
8.7, Ar), 7.67 (1H, d, J 2.0, Ar); 13C NMR (125 MHz, CDCl3) 24.7, 25.1, 25.1, 25.5, 28.6, 33.8, 33.8, 34.2, 44.1, 47.1, 
49.6, 53.4, 55.2, 112.3, 114.3, 119.7, 122.5, 127.6, 127.9, 129.4, 132.2, 154.6, 156.9, 158.9; MS (ESI+) m/z = 481.4 
[M+H]+. 
(S)-N-Benzyl-3-(2-benzyl-5-chloro-1H-benzo[d]imidazol-1-yl)piperidine-1-carbothioamide 16.  
General procedure C: 15{1} (16 mg, 49.2 µmol) and benzyl isothiocyanate (7.2 µl, 54.1 µmol). 16 (15 mg, 64%) as a 
white solid; HPLC purity (as area %) > 93; 1H NMR (500 MHz, CDCl3) 1.43 (1H, qt, J 4.1 and 13.3), 1.55 (1H, app.d), 
1.77-1.80 (1H, m), 2.25 (1H, qd, J 12.8 and 4.4), 3.03 (1H, td, J 13.4 and 2.4), 3.50 (1H, app.t), 4.35-4.46 (4H, m), 4.67-
4.71 (1H,m), 4.74 (1H, dd, J 14.6 and 4.6), 4.97 (1H, dd, J 14.6 and 5.4), 5.65 (1H, app.t, NH), 7.15-7.22 (6H, m, Ar), 
7.30-7.36 (6H, m, Ar), 7.73 (1H, d, J 2.0, Ar); 13C NMR (125 MHz, CDCl3) 24.5, 28.4, 35.0, 48.0, 50.4, 51.3, 52.7, 112.0, 
119.9, 122.7, 127.2, 127.7, 127.8, 127.9, 128.4, 128.8, 128.9, 132.1, 136.2, 137.8, 144.1, 154.5, 183.2. LC-MS (ESI+) 
m/z = 475.3 [M+H]+. 
(S)- 2-Benzyl-1-(1-(benzylsulfonyl)piperidin-3-yl)-5-chloro-1H-benzo[d]imidazole 17.  
Phenylmethanesulfonyl chloride (12 mg, 60.9 µmol, 1.1 eq) was added to a solution of 15 (18 mg, 55.4 µmol, 1eq) 
and triethylamine (11.6 µl, 83.1 µmol, 1.5 eq) in DCM (1mL). The mixture was stirred at RT for 1h, then quenched 
with water (3mL). The organic layer was separated, dried (MgSO4), and evaporated. Chromatography (5% DCM, 
methanol) gave 17 (25 mg, 94%) as a white solid; HPLC purity (as area %) > 96; 1H NMR (500 MHz, CDCl3) 1.34-1.41 
(2H, m), 1.64-1.68 (1H, m), 1.94 (1H, qd, J 12.6 and 4.2), 2.54 (1H, td, J 12.6 and 2.6), 3.01 (1H, app.t), 3.54 (1H, dd, J 
12.3 and 4.6), 3.61-3.64 (1H, m), 4.13 (1H, d, J 14.1), 4.17 (1H, d, J 14.1), 4.19 (1H, d, J 15.9), 4.24 (1H; tt, J 12.0 and 
4.1), 4.40 (1H, d, J 15.9), 7.11 (1H, d, J 8.7, Ar), 7.14 (1H, dd, J 8.7 and 1.8, Ar), 7.18-7.23 (3H, m, Ar), 7.27-7.30 (3H, 




General Procedure D:  
A mixture of 4-chloro-2-fluoronitrobenzene (1.0g, 5.7 mmol), the required benzylamine (5 eq), potassium carbonate 
(1.97g, 10.66 mmol) and ethanol (20 mL) was heated at 120 oC for 25 min in a microwave vial, then filtered and 
concentrated. The residue was diluted with ethylacetate (20 mL) washed with HCl (1N, 20 mL), water (20 mL) and 
brine (20 mL), dried (MgSO4) and concentrated. Recrystallisation from absolute ethanol gave 19 as bright orange-
yellow crystals.(45) 
N-Benzyl-5-chloro-2-nitroaniline 19{1} (52) 
General Procedure D: 4-chloro-2-fluoronitrobenzene (1.0 g, 5.7 mmol), benzylamine (2.79 mL, 25.6 mmol). 19{1} 66 
%; 1H NMR (300 MHz ,CDCl3) δ ppm 4.61 (d, J 5.3, 2H, CH2-N), 6-8 (m, 7H, Ar -H). 
5-Chloro-N-(3-chlorobenzyl)-2-nitroaniline 19{2} 
General Procedure D: 4-chloro-2-fluoronitrobenzene (1.0 g, 5.7 mmol), 3-chlorobenzylamine (2.79mL, 22.8mmol). 
19{2} 82 %; 1H NMR (300 MHz ,CDCl3) δ ppm 3.82 (s, 3H,OCH3), 4.51 (d, J 5.7, 2H, CH2-N), 6.61 (d, br, J 7.3 , 1H, Ar-H), 
6.84 (m, 5H, Ar-H), 8.11 (d, J 8.1, 1H, Ar-H), 8.46 (s, 1H, N-H). 
5-Chloro-N-(3-methoxybenzyl)-2-nitroaniline 19{3} 
General Procedure D: 4-chloro-2-fluoronitrobenzene (1.0g, 5.7 mmol), 3-methoxybenzylamine (2.9 7mL, 22.8 
mmol). 19{3} 82 %; 1H NMR (300 MHz ,CDCl3) 3.82 (s, 3H,OCH3), 4.51 (d, J 5.7, 2H, CH2-N), 6.61 (d, br, J 7.3,1H, Ar-H), 
6.84 (m, 5H, Ar-H), 8.11 (d, J 8.1, 1H, Ar-H), 8.46 (s, 1H, N-H). 
5-Chloro-N-(4-methoxybenzyl)-2-nitroaniline 19{4}(53) 
General Procedure D: 4-chloro-2-fluoronitrobenzene (1.0g, 5.7 mmol), 4-methoxybenzylamine (2.97mL, 22.8mmol), 
19{4} 82 %; 1H NMR (300 MHz ,CDCl3) δ ppm 3.73 (s, 3H,OCH3), 4.51 (d, J 5.7, 2H, CH2-N), 6.61 (d, br, J 7.3, 1H, Ar-H), 
6.81 (s, 1H, Ar-H), 6.92 (d, J 8.2, Ar-H), 8.11 (d, J 8.1, 1H, Ar-H), 8.36 (s, 1H, N-H). 
 
General Procedure E: Benzimidazole Intermediate Synthesis (20) 
A mixture 18 (0.3g, 1.41 mmol), sodium dithionite (0.67g, 3.84 mmol) and 19 (1.0 eq.) in methanol (16 mL) and water 
(4 mL) was heated by microwave for 10 mins at 100 oC, then diluted with ethyl acetate (20 mL), washed with water 
(20 mL) and brine (20 mL), dried (MgSO4) and evaporatated. Recrystallisation from ethyl acetate, petrol gave 20. 
4-(1-Benzyl-6-chloro-1H-benzoimidazole-2-yl)piperidine-1-carboxylic acid tert-butyl ester 20{1}  
General Procedure E: 19{1} (0.32g, 1.22mmol), sodium dithionite (0.64g, 3.66 mmol), 18 (0.29g, 1.34mmol). 20{1} 
77%; mp 157-158 oC; HPLC purity (as area %) > 96; 1H NMR (400 MHz ,CDCl3) 1.44 (s, 9H, tBu), 1.76 (m, br, 2H, CH2-
CH), 1.99 (m, br, 2H, CH2-CH), 2.73 (m, br 2H, CH2-N), 2.92 (m br, 1H, CH CH2), 4.25 (m, br, 2H, CH2N), 5.32 (s, 2H CH2 
N), 6.99 (d, 1H, J 1.7, Ar-H), 7.17 (s, 1H, Ar-H), 7.18 (m, 5H, Ar-H), 7.66 (d, 1H, 2.2 Hz, Ar-H); LC-MS (ESI+) m/z 426 
[M+H]+; IR 732, 819, 837, 1022, 1168.26, 1236, 1412, 2924 cm-1. 
tert-Butyl 4-(6-chloro-1-(4-chlorobenzyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate 20{2} 
General Procedure E: 19{2} (0.15g, 0.51 mmol), sodium dithionite (0.268g, 1.54 mmol), 18 (0.12g, 0.56mmol). 20{2} 
90%; mp 139-141 oC; HPLC purity (as area %) > 97; 1H NMR (400 MHz ,CDCl3) δ ppm: 1.43 (s, 9H, tBu), 1.76 (m, br, 2H, 
CH2-CH), 1.98 (m, br, 2H, CH2-CH), 2.72 (m, br 2H, CH2-N), 2.93 (m br, 1H, CH CH2), 4.22 (m, br, 2H, CH2N), 5.29 (s, 2H 
CH2 N), 6.70 (d, 1H, J 1.8, Ar-H), 6.99 (s, 1H, Ar-H), 7.19 (s, 1H, Ar-H), 7.25 (m, 3H, Ar-H), 7.61 (d, 1H, J 2.3, Ar-H); LC-
MS (ESI+) m/z 461 [M+H]+; IR 773, 1157, 1237, 1410, 1670, 2018, 2359, 2964 cm-1.  
 tert-Butyl 4-(6-chloro-1-(3-methoxybenzyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate 20{3}  
General Procedure E: 19{3} (0.36g, 1.23mmol), sodium dithionite (0.71g, 4.05mmol), 18 (0.29g, 1.35mmol). 20{3} 
73%; mp 142-143 oC; HPLC purity (as area %) > 97; 1H NMR (400 MHz ,CDCl3) 1.43 (s, 9H, tBu), 1.77 (m, br, 2H, CH2-
CH), 1.97 (m, br, 2H, CH2-CH), 2.71 (m, br 2H, CH2-N, 2.91 (m, br, 1H, CH CH2), 3.72 (s, 3H, OCH3) 4.22 (m, br, 2H, 
CH2N), 5.28 (s, 2H CH2 N), 6.51 (s, 1H, Ar-H), 6.53 (d, 1H, 1.8 Hz Ar-H), 6.77 (d, 1H, 1.72 Hz, Ar-H), 7.19 (s, 1H, Ar-H Cl), 
7.22 (m, 1H, Ar-H), 7.24 (d, 1H, Ar-H), 7.67 (d, 2.2 Hz, 1H, Ar-H); LC-MS (ESI+) m/z 456 [M+H]+; IR 821, 1043, 1398, 
1693, 2160, 2970 cm-1.  
tert-Butyl 4-(6-chloro-1-(4-methoxybenzyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate. 20{4} 
General Procedure E: 19{4} (0.29g, 1.0mmol) , sodium dithionite (0.52g, 3.0 mmol), 18 (0.23g, 1.1 mmol). 20{4} 90%; 
mp 142-143 oC; HPLC purity (as area %) > 91; 1H NMR (400 MHz ,CDCl3) 1.39 (s, 9H, tBu), 1.61 (m, br, 2H, CH2-CH), 
1.82 (m, br, 2H, CH2-CH), 2.70 (m, br 2H, CH2-N), 2.32 (m br, 1H, CH CH2), 3.69 (s, 3H, OCH3) 4.01 (m, br, 2H, CH2N), 
5.46 (s, 2H CH2 N), 6.86 (d, J 3, 2H, Ar-H), 7.10 (d, 2H, J 2.8, Ar-H), 7.15 (d, J 3.1, 1H, Ar-H), 7.58 (d, J 2.9, 1H, Ar-H), 
7.60 (s, 1H, Ar-H); LC-MS (ESI+) m/z 456 [M+H]+; IR υmax 809, 1030, 1236, 1416, 1682, 2163, 2927 cm-1. 
 
 General Procedure F: Boc deprotection 
A mixture of 20 (0.40 g, 0.94 mmol ), TFA (0.6 mL) and DCM (2 mL) was stirred at rt for 4.5 h, then concentrated and 
diluted with methanol (4 mL). K2CO3 (0.2 g) was added and the suspension was stirred at rt, then filtered, and 
concentrated. Chromatography (5% DCM, MeOH) gave 21. Intermediates 21{2},21{3}, 21{4} were used directly in the 
subsequent step without purification. 
1-Benzyl-6-chloro-2-(piperidin-4-yl)-1H-benzo[d]imidazole 21{1} 
A mixture of 20{1} (0.40 g, 0.94 mmol ), TFA (0.6 mL) and DCM (2 mL) was stirred at rt for 4.5 h, then concentrated 
and diluted with methanol (4 mL). K2CO3 (200mg) was added and the suspension was stirred at rt, then filtered, and 
concentrated. Chromatography (5% DCM, MeOH) gave 21{1} 72%; HPLC purity (as area %) > 98; 1H NMR (400 MHz 
,CDCl3) 1.62 (s. br. 1H, N-H)1.71 (m, br, 2H, CH2CH2-NH), 1.82 (m, 2H, CH2CH2-NH), 2.61 (m, 2H, CH2-CH2-NH), 2.82 (m, 
1H, CHCH2), 3.18 (d, br, 2H, J 11.4, CH2CH2-NH), 5.21 (s, 2H, CH2-N), 6.98 (m, 2H, J 1.4, 7.5, Ar-H), 7.09 (m, 1H, J 1.7, 
Ar-H), 7.12 (dd, 1H, J 1.91, 8.63, Ar-H), 7.25 (m, 3H, Ar-H), 7.60 (d, 1H, J 8.71, ArH); LC-MS (ESI+) m/z 326 [M+H]+.  
 General Procedure G: Benzimidazole Synthesis (9) 
21 (0.01 g, 0.028 mmol) was added to a solution of the appropriate isocyanate (1.2 eq.) in DCM (2 mL) and the 
mixture was stirred at rt for 1 h, then concentrated. Chromatography (NH-silica; 2% MeOH, DCM) gave 9 as glassy 
solids. 
Ethyl-4-(1-benzyl-6-chloro-1H-benzo[d]imidazole-2-yl)piperidine-1-carboxamido)benzoate 9{1,2} 
General Procedure G: 21{1} (0.008 g, 0.028 mmol), 4-acetylphenylisocyanate (0.005 g, 0.031 mmol). 9{1,2} 56%; 
HPLC purity (as area %) > 99; 1H NMR (400 MHz ,CDCl3) 1.89 (m, 2H, CH2CH), 2.05 (m, 2H, CH2NCO), 2.48 (s, 3H, CH3) 
3.04 (m, 2H, CH2NCO), 3.08 (m, 1H, CH2CH), 4.19 (m, 2H, CH2CH2NCO), 5.35 (s, 2H, CH2Ar), 6.58 (s, 1H, N-H), 7.05 (s, 
1H, Ar-H), 7.08 (d, 1H, J 1.8 Hz, Ar-H), 7.26 (m, 5H, Ar-H), 7.48 (d, 2H, J 8.91 Hz, Ar-H), 7.68 (d, 1H, J 7.76 Hz, Ar-H), 
7.91 (d, 2H, J 8.87 Hz, Ar-H) LC-MS (ESI+) m/z = 485 [M+H]+. 
Ethyl-4-(1-benzyl-6-chloro-1H-benzo[d]imidazole-2-yl)piperidine-1-carboxamido)benzoate 9{1,8} 
General Procedure G: 21{1} (0.012 g, 0.037 mmol), ethyl 4-isocyanobenzoate (0.008 g, 0.041mmol). 9{1,8} 8%; HPLC 
purity (as area %) > 99; 1H NMR (400 MHz ,CDCl3) 1.40 (t, 3H, J 7.1 Hz, OCH2CH3), 1.89 (m, 2H, CH2CH), 2.05 (m, 2H, 
CH2NCO), 3.04 (m, 2H, CH2NCO),3.08 (m, 1H, CH2CH), 4.19 (m, 2H, CH2CH2NCO), 4.37 (q, 2H, J 7.12 Hz, OCH2CH3), 
5.35 (s, 2H, CH2Ar), 6.58 (s, 1H, N-H), 7.05 (s, 1H, J 1.4 Hz, Ar-H), 7.08 (d, 1H, J 1.8 Hz, Ar-H), 7.26 (m, 5H, Ar-H), 7.48 
(d, 2H, J 8.9 Hz, Ar-H), 7.68 (d, 1H, J 7.7 Hz, Ar-H), 8.01 (d, 2H, J 8.9 Hz, Ar-H); LC-MS (ESI+) m/z = 517 [M+H]+. 
4-(1-Benzyl-6-chloro-1H-benzo[d]imidazol-2-yl)-N-(4-fluorophenyl)piperidine-1-carboxamide 9{1,9} 
General Procedure G: 21{1} (0.009 g, 0.028 mmol) was added to a stirred solution of 4-fluorophenylisocyanate (3.73 
μL, 0.033 mmol). 9{1,9} 30 %; HPLC purity (as area %) > 92; 1H NMR (400 MHz ,CDCl3) 1.79 (m, 2H, CH2CH2-NH), 1.97 
(m, 2H, CH2CH2-NH), 2.91 (m, 3H, CH2-CH2-NH, CH-CH2), 4.12 (m, 2H, CH2-N), 5.22 (s, 2H, CH2-N), 6.38 (s, 1H, N-H), 
6.89 (m, 2H, Ar-H-F), 6.87 (s, 1H, Ar-H), 6.92 (br d, 1H, J 1.94, Ar-H), 7.15 (br s, 1H, Ar-H), 7.19 (m, 2H, , Ar-H), 7.25 
(m, 5H, Ar-H), 7.60 (d, 1H, 8.7 Hz, Ar-H).; LC-MS (ESI+) m/z 463 [M+H]+.  
4-(1-Benzyl-6-chloro-1H-benzo[d]imidazole-2-yl)-N-cyclohexylpiperidine-1-carboxamide 9{1,10}  
General Procedure G: 21{1} (0.011g, 0.032mmol), cyclohexylisocyanate (0.004 g, 0.036 mmol). 9{1,10} 68%; HPLC 
purity (as area %) > 98; 1H NMR (400 MHz ,CDCl3) 1.09 (m, 3H, cyclohexyl), 1.28 (m, 2H, CH2CH-NH), 1.52 (m, 1H, 
cyclohexyl), 1.62 (m, 2H, cyclohexyl), 1.71 (m, 2H, CH2-CH2-N), 1.85 (m, 2H, cyclohexyl), 1.91 (m, 2H, cyclohexyl), 2.74 
(m, 2H, CH2-NCO), 2.85 (m, 1H, NH-CH2), 3.54 (m, 1H) 3.93 (br d, 2H, J 14.59, CH2CH), 4.19 (br d, 1H, N-H), 6.85 (m, 
1H, Ar-H), 6.87 (d, 1H, J 2.27 ), 7.12 (m, 1H, , Ar-H), 7.19 (dd, 1H, J 2.20, 7.89, Ar-H), 7.25 (m, 3H, Ar-H), 7.61 (d, 1H, 
9.39 Hz, Ar-H).; LC-MS (ES+) m/z 451 [M+H]+.  
N-(4-Acetylphenyl)-4-(6-chloro-1-(3-chlorobenzyl)-1H-benzo[d]imidazole-2-yl)piperidine-1-carboxamide 9{2,2} 
General Procedure G: 21{2} (0.011 g, 0.029mmol), 4-acetylphenylisocyanate (0.005 g, 0.032 mmol). 9{2,2} 81%; HPLC 
purity (as area %) > 99; 1H NMR (400 MHz ,CDCl3) 1.88 (m, 2H, CH2CH), 2.09 (m, 2H, CH2NCO), 2.49, (s, 3H, COCH3) 
2.99 (m, 2H, CH2NCO), 3.07(m, 1H, CH2CH), 4.17 (m, 2H, CH2CH2NCO), 5.31 (s, 2H, CH2Ar), 6.49 (s, 1H, N-H), 6.85 (m, 
1H, Ar-H), 7.06 (s, 1H, Ar-H), 7.14 (d, 2H, J 8.37 Hz, Ar-H) 7.17 (d, 1H, J 1.82 Hz, Ar-H), 7.39 (d, 3H, J 7.91 Hz Ar-H), 
7.38 (d, 2H, J 8.85 Hz, Ar-H), 7.81 (d, 1H, J 8.56 Hz, Ar-H); LC-MS (ESI+) m/z = 519 [M+H]+. 
4-(6-Chloro-1-(3-chlorobenzyl)-1H-benzo[d]imidazol-2-yl)-N-(3,4,5-trimethoxyphenyl)piperidine-1-carboxamide 
9{2,3} 
General Procedure G: 21{2} (0.05 g, 0.14 mmol), 3,4,5-trimethoxyphenylisocyanate (0.035 g, 0.16 mmol). 9{2,3} 73 
%; HPLC purity (as area %) > 92; 1H NMR (400 MHz ,CDCl3) 1.82 (m, br, 2H, CH2CH2-NH), 2.10 (m, 2H, CH2CH2-NH), 
2.99 (m, 3H, CH2-CH2-NH, CH-CH2), 3.73 (s, 3H, Ar-OMe), 3.77 (s, 6H, Ar-(OMe)2), 4.12 (m, 2H, CH2-N), 5.27 (s, 2H, 
CH2-N), 6.31 (s, 1H, N-H), 6.59 (s, 2H, Ar-H), 6.72 (d,1H, J 7.21, Ar-H), 7.01 (s, 1H, Ar-H), 7.13 (m, 3H, Ar-H), 7.62 (d, 
1H, 8.33 Hz, Ar-H); LC-MS (ESI+) m/z 569 [M+H]+;  
4-(6-Chloro-1-(3-chlorobenzyl)-1H-benzo[d]imidazole-2-yl)-N-(4-(trifluoromethoxyphenyl)piperidine-1-
carboxamide 9{2,4} 
General Procedure G: 21{2} (0.011g, 0.029mmol), 4-trifluoromethoxyphenylisocyanate (0.004g, 0.032mmol). 9{2,4} 
79%; HPLC purity (as area %) > 99; 1H NMR (400 MHz ,CDCl3) 1.88 (m, 2H, CH2CH), 2.09 (m, 2H, CH2NCO), 2.99 (m, 2H, 
CH2NCO), 3.07(m, 1H, CH2CH), 4.17 (m, 2H, CH2CH2NCO), 5.31 (s, 2H, CH2Ar), 6.49 (s, 1H, N-H), 6.85 (m, 1H, Ar-H), 
7.06 (s, 1H, Ar-H), 7.14 (d, 2H, J 8.37 Hz, Ar-H) 7.17 (d, 1H, J 1.8 Hz, Ar-H), 7.35 (m, 3H, Ar-H), 7.38 (d, 2H, J 8.8 Hz, Ar-
H), 7.69 (d, 1H, J 8.6 Hz, Ar-H); LC-MS (ESI+) m/z = 561 [M+H]+. 
Ethyl 3-(4-(6-chloro-1-(3-chlorobenzyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxamido)benzoate 9{2,7} 
General Procedure G: 21{2} (0.011g, 0.029mmol), ethyl 3-isocyanobenzoate (0.006g, 0.032mmol). 9{2,7} 75 %; HPLC 
purity (as area %) > 98; 1H NMR (400 MHz ,CDCl3) δ ppm: 1.40 (t, 3H, J 7.11 Hz, OCH2CH3), 1.89 (m, 2H, CH2CH), 2.05 
(m, 2H, CH2NCO), 3.04 (m, 2H, CH2NCO),3.08 (m, 1H, CH2CH), 4.19 (m, 2H, CH2CH2NCO), 4.37 (q, 2H, J 7.12 Hz, 
OCH2CH3), 5.35 (s, 2H, CH2 benzylamine), 6.58 (s, 1H, N-H), 6.85 (m, 1H, Ar-H), 7.06 (s, 1H, Ar-H), 7.21 (d, 1H, J 1.82 
Hz, Ar-H), 7.38 (m, 3H, Ar-H), 7.71 (m, 3H, Ar-H), 7.85 (m, 1H, Ar-H);LC-MS (ESI+) m/z = 549 [M+H]+.  
Ethyl-4-(4-(6-chloro-1-(3-chlorobenzyl)-1H-benzo[d]imidazole-2-yl)piperidine-1-carboxamido) benzoate 9{2,8}  
General Procedure G: 21{2} (0.011g, 0.029mmol), ethyl 4-isocyanobenzoate (0.006g, 0.032mmol). 9{2,8} 80%; HPLC 
purity (as area %) > 98; 1H NMR (400 MHz ,CDCl3) 1.40 (t, 3H, 7.11 Hz, OCH2CH3), 1.89 (m, 2H, CH2CH), 2.05 (m, 2H, 
CH2NCO), 3.04 (m, 2H, CH2NCO), 3.08 (m, 1H, CH2CH), 4.19 (m, 2H, CH2CH2NCO), 4.37 (q, 2H, J 7.12 Hz OCH2CH3), 
5.35 (s, 2H, CH2Ar), 6.58 (s, 1H, N-H), 6.85 (m, 1H, Ar-H), 7.06 (s, 1H, Ar-H), 7.21 (d, 1H, J 1.82 Hz, Ar-H), 7.38 (m, 3H, 
Ar-H), 7.43 (d, 2H, J 8.83 Hz, Ar-H), 7.69 (d, 1H, J 8.56 Hz, Ar-H), 7.97 (d, 2H, J 8.77 Hz, Ar-H; LC-MS (ESI+) m/z = 549 
[M+H]+.  
4-(6-Chloro-1-(3-chlorobenzyl)-1-H-benzo[d]imidazole-2-yl)-N-cyclohexylpiperidine-1-carboxamide 9{2,10} 
General Procedure G: 21{2} (0.011g, 0.029mmol), cyclohexylisocyanate (4.13μL, 0.032mmol). 9{2,10} 63 %; HPLC 
purity (as area %) > 92; 1H NMR (400 MHz ,CDCl3) 1.12 (m, 2H, cyclohexyl), 1.15 (m, 2H, cyclohexyl), 1.39 (m, 2H, 
cyclohexyl), 1.82 (m, 2H, CH2-CHN),1.91 (m, 2H, CH2NCO) 2.11 (m, 2H, CH2-CHN), 2.85 (m, 2H, CH2CH2), 2.93 (m, 1H, 
CHCH2), 3.65 (m, 1H, CHCH2), 4.11 (m, 2H), 4.35 (d, 1H, J 7.5 Hz, N-H), 5.35 (s, 2H, CH2N), 6.90 (br d, 1H, J 6.90 Hz, Ar-
H benzimidazole), 7.12 (br s, 1H, Ar-H benzylamine), 7.21 (d, 1H, J 1.7 Hz, Ar-H), 7.31 (m, 3H, Ar-H benzylamine), 7.8 
(d, 1H, J 9.0 Hz, Ar-H); LC-MS (ESI+) m/z = 483 [M+H]+.  
Ethyl 4-(4-(6-chloro-1-(3-methoxybenzyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxamido)benzoate 9{3,8} 
General Procedure G: 21{3} (0.01 g, 0.028 mmol), ethyl 4-isocyanobenzoate (0.006 g, 0.031 mmol). 9{3,8} 68%; HPLC 
purity (as area %) > 99; 1H NMR (400 MHz ,CDCl3) 1.40 (t, 3H, J 7.11 Hz, OCH2CH3), 1.96 (m, 2H, CH2CH), 2.08 (m, 2H, 
CH2CH), 3.04 (m, 3H, CH2CH), 3.79 (s, 3H, OMe), 4.21 (m, 2H, CH2CH2NCO), 4.35 (q, 2H, J 7.1 Hz CH2CH3), 5.34 (s, 2H, 
CH2Ar), 6.61 (m, 3H, NHCO, Ar-H), 6.85 (m, 1H, Ar-H), 7.21 (m, 3H, ArH), 7.48 (d, 2H, Ar-H), 7.68 (d, 1H, J 7.8 Hz, Ar-
H), 7.91 (d, 2H, J 8.30 Hz, Ar-H); LC-MS (ES+) m/z = 547 [M+H]+. 
Ethyl 3-(4-(6-chloro-1-(3-methoxybenzyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxamido) benzoate 9{3,7} 
General Procedure G: 21{3} (0.01 g, 0.028 mmol), ethyl 4-isocyanobenzoate (0.006 g, 0.031 mmol). 9{3,7} 72%; HPLC 
purity (as area %) > 99; 1H NMR (400 MHz ,CDCl3) 1.39 (t, 3H, J 7.11 Hz, OCH2CH3), 1.91 (m, 2H, CH2CH), 2.11 (m, 2H, 
CH2CH), 3.04 (m, 3H, CH2NCO), 3.78 (s, 3H, OMe), 4.22 Hz (m, 2H, CH2CH2NCO), 4.39 (q, 2H, J 7.13 Hz, CH2CH3), 5.34 
(s, 2H, CH2Ar), 6.57 (m, 3H, NHCO, ArH), 6.87 (m, 1H, ArH), 7.20 (m, 2H, ArH), 7.45 (m, 2H, ArH) 7.70 (m, 3H, ArH), 
7.81 (s, 1H, ArH); LC-MS (ESI+) m/z 547 [M+H]+. 
4-(6-Chloro-1-(3-methoxybenzyl)-1H-benzo[d]imidazole-2yl)-N-(4-(trifluoromethoxy)phenyl)piperidine-1-
carboxamide 9{3,4}  
General Procedure G: 21{3} (0.01 g, 0.028 mmol), 4-trifluoromethoxyphenylisocyanate (0.005 g, 0.031 mmol). 9{3,4}, 
41%; HPLC purity (as area %) > 96; 1H NMR (400 MHz ,CDCl3) 1.99 (m, 2H, CH2CH), 2.08 (m, 2H, CH2CH), 3.02 (m, 3H, 
CH2NCO), 3.77 (s, 3H, OMe), 4.19 Hz (m, 2H, CH2CH2NCO), 5.34 (s, 2H, CH2Ar), 6.57 (m, 3H, NHCO, ArH), 6.86 (m, 1H, 
ArH), 7.14 (d, 2H, J 8.4 Hz, ArH), 7.21 (m, 3H, ArH), 7.35 (d, 2H, J 8.5 Hz, ArH), 7.66 (m, 2H, Ar-H); LC-MS (ESI+) m/z = 
559 [M+H]+. 
N-(4-Acetylphenyl)-4-(6-chloro-1-(3-methoxybenzyl)-1H-benzo[d]imidazole-2-yl)piperidine-1-carboxamide 9{3,2} 
General Procedure G: 21{3} (0.01 g, 0.028 mmol), 4-acetylphenylisocyanate (0.004 g, 0.024 mmol). 9{3,2} 67%; HPLC 
purity (as area %) > 99; 1H NMR (400 MHz ,CDCl3) 1.97 (m, 2H, CH2CH), 2.11 (m, 2H, CH2CH), 2.48 (s, 3H, CH3), 3.02 
(m, 3H, CH2NCO), 3.72 (s, 3H, OMe), 4.19 Hz (m, 2H, CH2CH2NCO), 5.35 (s, 2H, CH2 benzylamine), 6.57 (m, 3H, 13 Hz, 
N-H-urea, Ar- H- OMe, Ar- H-OMe), 6.86 (m, 1H, 7.13 Hz, Ar-H-Cl), 7.22 (m, 3H, 3-8 Hz Ar-H), 7.49 (d, 2H, 8.7 Hz, Ar-H-
COCH3), 7.71 (d, 1H, 9.2 Hz Ar-H-Cl), 7.99 (d, 2H, 8.68 Hz Ar-H-COCH3). LC-MS (ES+) m/z 517 [M+H]+. 
4-(6-Chloro-1-(4-methoxybenzyl)-1H-benzo[d]imidazol-2-yl)-N-(4-nitrophenyl)piperidine-1-carboxamide 9{4,1} 
General Procedure G: 21{4} (0.05g, 0.14mmol), paranitrophenylisocyanate (0.025g, 0.16mmol.). 9{4,1} 63%; HPLC 
purity (as area %) > 89; 1H NMR (400 MHz ,CDCl3) 1.93 (d, br, 2H, J 14.79, CH2-NC(O)), 2.13 (m, br, 2H, CH2CH2-N ), 
3.12 (m, br, 2H, CH2-CH2-N), 3.73 (s, 3H, Ar-OMe), 3.77 (s, 3H, Ar-OMe), 4.11 (br d, 2H, J 13.34, CH2-CH2-N), 5.28 (s, 
2H, N-CH2(Ar)), 6.66 (s, 1H, N-H-Ar), 6.89 (d, 2H, J 8.61, 2H, Ar-H), 6.99 (d, 2H, J 8.73, Ar-H), 7.24 (d, 1H, J 2.5, Ar-H), 
7.30 (s, 1H, Ar-H), 7.50 (d, 2H, J 8.19, Ar-H), 7.69 (d, 1H, Ar-H), 8.22 (d, 2H, J 8.19, Ar-H); LC-MS (ESI+) m/z 520 
[M+H]+.  
N-(4-Acetylphenyl)-4-(6-chloro-1-(4-methoxybenzyl)-1H-benzo[d]imidazol-2-yl)piperidine-1-carboxamide 9{4,2} 
General Procedure G: 21{4} (0.097g, 0.27mmol), 4-acetylphenylisocyanate (0.074g, 0.46mmol). Chromatography 
(50% EtOAc, petrol), 9{4,2} 55 %; HPLC purity (as area %) > 96; 1H NMR (400 MHz ,CDCl3) 1.82 (m, 2H, CH2CH2-NH), 
2.05 (m, 2H, CH2CH2-NH), 2.48(s, 3H, Ar-COCH3) 2.94 (m, 3H, CH2-CH2-NH and CH-CH2), 3.71 (s, 3H, Ar-OMe), 4.12 (m, 
br 2H, CH2-N), 5.22 (s, 2H, CH2-N), 6.62 (s, 1H, N-H), 6.79 (d, 2H, J 8.7, Ar-H), 6.84 (d, 2H, J 8.7, Ar-H), 7.18 (m, 2H, Ar-
H), 7.39 (d, 2H, J 8.8, Ar-H), 7.6 (dd, 1H, J 8.1, 1.04, Ar-H), 7.89 (d, 2H, J 8.8, Ar-H).; LC-MS (ESI+) m/z 517 [M+H]+.  
4-(6-Chloro-1-(4-methoxybenzyl)-1H-benzo[d]imidazol-2-yl)-N-(3,4,5-trimethoxyphenyl)piperidine-1-carboxamide 
9{4,3}  
General Procedure G: 21{4} (0.05g, 0.14mmol), 3,4,5-trimethoxyphenylisocyanate (0.033 g, 0.16 mmol). 9{4,3} 61%; 
HPLC purity (as area %) > 94; 1H NMR (400 MHz, CDCl3) 1.91 (d, br, 2H, J 14.75, CH2-NC(O)), 2.11 (m, br, 2H, CH2CH2-N 
), 3.02 (m, br, 2H, CH2-CH2-N), 3.82 (s, 3H, Ar-OMe), 3.84 (s, 3H, Ar-OMe), 3.88 (s, 6H, Ar-OMe), 4.11 (d, br, 2H, J 
13.34, CH2-CH2-N), 5.32 (s, 2H, N-CH2(Ar)), 6.29 (s, 1H, N-H-Ar), 6.88 (d, J 8.61, 2H, Ar-H), 6.98 (d, 2H, J 8.73, Ar-H), 
7.24 (d, 1H, J 2.5, Ar-H), 7.26 (s, 1H, Ar-H), 7.69 (d, 1H, Ar-H); LC-MS (ESI+) m/z 565 [M+H]+.  
 
 
 
 
